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Cancer is a major public health problem as one of the leading in causes of burden and 
causes of death diseases with more than one death by cancer among 8 deaths by all 
causes in global. The cancer mortality is even much higher in Singapore with more than 
25% of deaths by cancer among all deaths. It is due to the lack of new generation of 
anticancer drugs with high chemotherapeutic effectiveness and low side-effects. 
Therefore, investigation of drug delivery systems using polymeric micelles as carriers 
with the enhancement in therapeutic efficacy, high selectivity and binding affinity to 
cancer cells has been aimed in this project for different cancer treatments. 
 
Most of current clinical therapies are not sufficient to cancer treatments due to the non-
specific delivery of therapeutic agents to healthy cells and the less penetration of 
therapeutic agents into cancer cells. The first objective of this work is to develop an 
effective system for anticancer drug delivery. The system has been developed for 
physically encapsulating of hydrophobic drugs because most of anticancer drugs are 
hydrophobic in nature. Self-assembled polymeric micelles based on biodegradable 
amphiphilic copolymer poly(D,L-lactide-co-glycolide)-poly(ethylene glycol)(PLGA-
PEG) have been multi-functionalized using folate targeting moiety (FOL) and a cell 
penetrating peptide (TAT) to enhance the tumor targeting ability and the cellular uptake 
of carriers. The concentration of FOL and TAT combined modification on the carrier 
surface has been optimized.  
 
 X 
Another strategy to reduce toxic side effects of chemotherapy is the treatment by 
combining different classes of chemotherapeutic drugs. Besides the reduction of side 
effects, enhancement in therapeutic efficacy can also be achieved at synergistic treatment 
combinations. Therefore, targeting delivery of combinations of two classes of anticancer 
drugs has been developed based on the optimized FOL/TAT-modified micellar system in 
the earlier study to further improve the treatment efficacy. The synergism in combination 
therapy depends on many factors such as the therapeutic mechanism of the drugs, the 
respond of certain cell lines to drugs, the combination ratio. A combined chemo-drug 
system for cancer treatments based on an antitumor antibiotic agent (doxorubicin, DOX) 
and a mitotic inhibitor agent (paclitaxel, PTX); and a combined system of PTX and a 
hormone drug (tamoxifen, TAM) for breast cancer treatment have been investigated.  
 
Although PLGA-PEG micellar system can be used successfully in encapsulation of 
hydrophobic anticancer drugs, it is not suitable for encapsulation of platinum-based 
anticancer drugs due to the low hydrophobic interactions between the drugs and the 
hydrophobic core of micelles. Another suitable micellar system for targeting delivery of a 
platinum drug (cisplatin, CDDP) has been demonstrated using the polymer-drug complex 
system based on poly(ethylene glycol)-poly(glutamic acid) (PEG-PGA) and folate-PEG-
PGA (FOL-PEG-PGA). Moreover, this system shows potentially for encapsulation of 
positive charged drug due to the negative charged of the PGA block. Targeting delivery 
of DOX has been studied using this micellar system as a high DOX loading system due to 
the electrostatic interaction between DOX and PGA. Further enhancement in cancer 
 XI 
treatment efficacy has been investigated by the targeting delivery of CDDP and DOX 
simultaneously for advanced solid cancer treatments.  
 
 This is the first study that has utilized the combined advantages of (1) synergistic effect 
of combined drugs, (2) polymeric carrier for drug delivery with sustained release and 
biocompatibility properties, (3) carrier modifications with targeting moiety to enhance 
the delivery selectivity and/or with penetrating peptide to enhance the uptake. The 
comparisons between the co-delivery of two single drug-loaded carrier systems and the 
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Cancer is a major public health problem because it is one of the leading causes of burden 
and causes of death diseases. Although cancer disease has been exiting for many 
centuries, it becomes a more and more common disease all over the world. As reported 
by World Health Organization, there were 12.4 million new cancer cases and 7.6 million 
cancer deaths in 2008 [1]. With the increase in the global population, the number of new 
cases of cancer has been increased from 5.9 million in 1975 to 12.4 million in 2008 as 
shown in Figure 1.1. It was estimated by the International Agency for Research on 
Cancer (IARC) that the new cancer incidence was expected to rise from 12.4 million in 
2008 to 26.4 million in 2030 with the growth in the world population from 6.7 billion in 
2008 to 8.3 billion by 2030. 
 
Figure 1.1 Estimated global cancer incidence, 1975-2030 [1]. 
 
 2 
Due to the huge worldwide health burden of cancer, the ultimate efforts of scientists, 
researchers and society have been put on the improvement of diagnostic devices and 
treatments over decades. Cancer therapy can be listed into three methods including 
surgery, radiation therapy and chemotherapy. In chemotherapy, the severe side-effects 
and less effectiveness of anticancer drugs are still present. Therefore, the focus in 
anticancer drug research has been increasing recently. As can be seen in industry 
therapeutic area (Figure 1.2), the research focus was shifted from hypertension therapy in 
2001 to cancer in 2010.  
 
Figure 1.2 Changes in therapeutic area focus from 2001 to 2010 [2]. 
 
With the mission on enhancing cancer therapeutic efficacy around the world, many new 
anticancer drugs have been discovered every year with the enhancement in treatment 
effectiveness. Clearly, the trends in cancer mortality rates of both male and female in the 
United States and Singapore have been declined as shown in Figure 1.3. It can be seen 
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that the incidence rates of male keep almost unchanged recently while the incidence rates 
of female increase. Although the incidence rates increase in general, the declining in the 
mortality rates are still observed. In addition, the 5-year relative survival ratios gradually
 
Figure 1.3 Trends in cancer incidence and mortality by gender: (A) United States, 1975-
2008 [3]; (B) Singapore, 1968-2010 [4, 5]. 
 
increase for both genders in the period of 1973-2007 in Singapore (Figure 1.4) [4]. The 5-
year relative survival ratios of male and female cancer patients in Singapore improve 
from 13.6% and 28.3% in the period of 1973-1977 to 44.6% and 57.5% in 2003-2007, 
respectively. These observations indicate the valuable contribution of the global effort in 
enhancing the cancer therapeutic effectiveness to eliminating cancer as a major health 
problem. Although many new anticancer drugs have been developed, cancer death is still 
rated as one of the most death disease, even more than HIV/AIDS with approximate one 
in every eight deaths of all causes in global and more than 25% deaths of all causes in 
Singapore (Figure 1.5). 
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Figure 1.4 Trends in 5-year relative survival ratio, Singapore, 1973-2007 [4]. 
 
Therefore, a continued focus on investigating new generation anticancer agents is needed 
to increase the effectiveness of anticancer agents while reducing the side effects to 
increase the quality of cancer patient’s life. 
 
 
Figure 1.5 Trends in the percentage of cancer deaths among deaths of all causes, 
Singapore, 1968-2007 [4]. 
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1.1.2 Limitation of traditional chemotherapeutic technology for cancer treatments 
Chemotherapy is a common method for cancer treatments and is the most effective 
method for metastatic cancer treatments. However, the traditional chemotherapeutic 
drugs, which are small-molecules and toxic drugs, remain low success rate due to their 
delivered blindly to healthy tissues which lead to severe harmful side-effects,  limited 
accessibility of drugs to the tumor tissue, their intolerable toxicity, development of multi-
drug resistance, and the dynamic heterogeneous biology of the growing tumors [6, 7]. 
Therefore, chemotherapeutic systems using biocompatible nanocarriers have been 
developed as an emerging platform to deliver the anticancer drugs selectively to tumor 
cells. Doxil is the first drug-loaded carrier that was approved in 1995 using polyethylene 
glycol (PEG) modified-liposome to encapsulate doxorubicin (DOX). DOX is an effective 
anticancer drug that can be used effectively for many cancer treatments. However, DOX 
also causes severe side-effects that result in the serious heart damage to cancer patients. 
By encapsulating DOX into a nanocarrier, the serious heart damage incidence of this 
system (Doxil) treated patients has been reduced by 3 times compared with that of 
traditional DOX treated patients [8].  
 
1.1.3 Requirements for an ideal drug delivery system 
In order to overcome the limitations of the traditional chemotherapeutic technology and 
more effective in cancer therapy, anticancer drugs should be delivered in high molecular 
carrier systems that (1) are hydrophilic [9], biocompatible and non toxic; (2) exhibit 
prolonged circulation in the blood stream by having molecular weights and sizes of more 
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than 50,000 and 6 nm, respectively [9, 10]; (3) have sustained delivery property; and (4) 
have higher selectivity and affinity to tumor cells than healthy cells.  
 
1.2 Hypotheses 
The key hypotheses of this work are defined as such: 
(1) To meet the specialized requirements of drug delivery system, it has been 
hypothesized that hydrophobic drugs can be physically loaded into PEG-PLGA 
micelles and the resultant drug-loaded micelles exhibit suitable properties for drug 
delivery. 
(2) Multi-modification of micelles with different moieties which are specially used 
for drug delivery systems can increase the treatment efficacy of the resultant 
micelles compared to that of single-moiety modified one.  
(3) It has been further hypothesized that the drug delivery system is more effective 
when synergistic combinations of anticancer drugs are co-encapsulated into the 
micelles. 
(4) Polymeric micelles can also be used as carriers for hydrophilic drug delivery if 
the drugs and polymers exhibit specific chemical interactions. 
 
1.3 Objectives and scope of the study 
The objectives of this thesis are to investigate and demonstrate polymeric micellar drug 
delivery systems for cancer therapy to address the limitations of the traditional 
chemotherapeutic technology. In addition, the newly developed systems in this study 
have also been aimed to maximize the therapeutic effect and to satisfy the requirements 
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for an ideal drug delivery system as mentioned above. Therefore, multifunctional 
delivery systems (Figure 1.6) which are aimed for working in a synergistic manner have 
been investigated in this work. These multifunctional systems contain three main design 
components: a platform material (polymer micelle), encapsulated active agents (anti-
cancer drugs), and functional ligands. 
 
Figure 1.6 Schematic of multifunctional drug delivery system. 
 
The specific aims of this research include: 
(1) Development a carrier system for hydrophobic drug delivery for enhanced 
delivery of anticancer drugs to cancer cells, prolonged the circulation and 
sustained release. Self-assembled polymeric micelles based on biodegradable 
copolymer poly(D,L-lactide-co-glycolide)-poly(ethylene glycol)(PLGA-PEG) 
have been chosen due to the well-known bioavailability of PLGA and PEG 
polymers. This system has been multi-functionalized using folate targeting moiety 
(FOL) and cell penetrating peptide TAT to enhance the tumor targeting ability 
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and the cellular uptake. Optimization has been carried to investigate the suitable 
concentration of FOL and TAT combined modification on the carrier surface. 
 
(2) Investigation the synergistic effect of combined chemotherapy of doxorubicin 
(DOX) and paclitaxel (PTX). Firstly, the effects of combined DOX and PTX at 
various ratios have been studied to investigate the synergistic regime. Secondly, 
the effect of co-delivery of the two drugs encapsulated separately into the 
mentioned TAT/FOL modified system has been investigated. Finally, the 
simultaneously encapsulation of the two drugs into the TAT/FOL modified 
micelle have been demonstrated.  
 
(3) Study the dual-functionalized micellar system for synergistic delivery of two 
anticancer drugs for breast cancer treatment. Tamoxifen (TAM), a hormone drug, 
prevents the effects of estrogen to breast cancer cells [11]. PTX, a chemo-drug, 
kills cancer cells by promoting microtubule assembly from tubulin dimmers, 
stabilizes microtubules by preventing depolymerization [12]. Therefore, 
combined treatment of TAM and PTX has been investigated using TAT/FOL 
modified micellar system to demonstrate the enhancement of the system by 
utilizing the synergistic effect of the combination of two drugs and the 
enhancement in tumor accumulation via TAT/FOL modification for breast cancer 
treatment.   
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(4) Design a drug delivery system with high drug loading ability for the 
chemotherapy using a platinum-based drug and DOX. Cisplatin (CDDP) is a 
powerful drug for various cancer treatments but it exhibits serious side effects 
including acute and chronic nephrotoxicity, myelosuppression [13]. Therefore, 
delivery of CDDP using a carrier is essential. In addition, a non-platinum based 
drug (DOX) has been combined with CDDP to enhance the therapeutic efficacy 
based on the synergistic effect of the combined treatment.  Combined treatment of 
CDDP and DOX has been demonstrated using the polymer-drug complex system 
based on poly(ethylene glycol)-poly(glutamic acid) (PEG-PGA) and folate-PEG-
PGA (FOL-PEG-PGA) polymers. 
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CHAPTER 2. Literature Review 
 
2.1 Cancer treatment 
Cancer, medically termed as malignant neoplasm, is a class of disease in which abnormal 
cells divide without control, invade other near end tissues and finally metastasis via blood 
and lymph node vessels to other organs as insulated in Figure 2.1 [14]. Cancer is 
normally caused by the genetic mutation in transformed cells and exhibits in many types 
mainly including carcinoma, sarcoma, leukemia, glioma, lymphoma and myeloma.  
 
 
Figure 2.1  Development of cancer from the primary tumor to metastatic site [14].  
 
Cancer can be treated by several methods depends on the type, the location and the stage 
of the disease and the patient’s conditions. Common methods for cancer treatment are 
surgery, radiation therapy, immunotherapy, hormone therapy and chemotherapy. Surgery 
is the oldest known method that can be used to remove the cancer without affecting the 
normal tissues if the cancer has not spread to other parts of the body. However, the 
patient has to experience the physical pain and the high danger of infections. The patient 
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may also suffer from the rapid growth of the remaining cancer cells which can cause 
metastatic cancer if the cancer cells have not been removed completely by the surgery. In 
radiation therapy, cancer cells are destroyed by high energy particles or waves. It is one 
of the common and valuable tools for the treatment of local and regional cancer, similar 
to surgery. Immunotherapy, also called as biologic therapy, is a therapeutic strategy 
including monoclonal antibodies, non-specific immunotherapies and cancer vaccines. It 
is designed to boost the patient’s immune system to work harder or smarter to attack 
cancer cells. It can be used to destroy cancer cells, stop or slow the growth of cancer 
cells, reduce the spreading speed of cancer cells. It is likely to be effective for treating of 
the early stage cancer with less toxicity to patient’s body. Hormone therapy treats the 
cancer cells by altering the growth and activity of hormones in the body that inhibits the 
growth of cancer cells. Hormone therapy is commonly used to treat breast cancer [15-20] 
and prostate cancer [21-23]. Chemotherapy is an effective method using 
chemotherapeutical agents to treat cancer that has spread or metastasized because the 
medicines can travel throughout the entire body. Chemotherapy usually treats cancer via 
damaging to DNA or RNA of cancer cells. Although hundreds of chemotherapeutical 
agents have been developed for clinical use, their applications are still limited due to the 
serious side-effect to normal tissues, poor water-solubility, and short circulation time.  
 
2.2 Traditional cancer chemotherapy technology 
Traditional cancer chemotherapy is the treatment using one or more small-molecule 
anticancer drugs which aim to destroy the rapidly dividing cells via their specific 
mechanisms to the cells. Chemotherapeutic drugs are very strong to fight against a 
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spectrum of cancers from the early stage to the metastatic stage due to their broad range 
of mechanism to cancer cells (Table 2.1) [24]. Although the mechanisms of action are 
different among them, they all rely on the rapid and uncontrolled proliferation and 
division properties of cancer cells. They attack the cell division and apoptosis pathways. 
 
Table 2.1 Anticancer therapeutic and their mechanism of action [24]. 
 
 
Unfortunately, besides the remarkable achievement of chemotherapy in cancer treatment, 
there are still many uncontrollable in the typical chemotherapy factors that challenge the 
treatment efficacy. Due to the small size with inability to target selectively to tumor cells 
(Figure 2.2), traditional chemotherapeutic drugs attack the proliferation of normal cells 
that causes toxic to healthy tissues with serious side-effects including hair loss, appetite 
loss, nausea, vomiting, anemia, nerve damage, memory loss, and permanent organ 
damage to heart, lung, liver and kidneys [25-29]. In addition, treatments using these 
small-molecule anticancer drugs exhibit some difficulties such as poor solubility [30], 
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sensitivity to degradation, instability, rapid clearance, and fast development of multiple-
drug resistance (MRD).  
 
 
Figure 2.2 Schematic representation of the delivery mechanism of small-molecule drugs 
to tumors [31]. 
 
2.3 Drug delivery technology 
To overcome the limitations of the typical chemotherapy, drug delivery systems have 
been developed to generate new therapeutic systems with better treatment efficacy and 
lower side effects.  Numerous drug delivery systems (Figure 2.3) have been developed 
with different designs including liposomes, micelles, nanoparticles, polymer-drug 
conjugates, dendrimer, silica nanoparticle, carbon nanotubes, and metallic particles [8, 
32-38]. Although the designs and materials of these delivery systems are different, they 
are all developed based on the same aims which are able to deliver the right dose of drugs 
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in the active condition to the targeted tissues without causing side-effects or drug 
resistance to tumor cells.  
 
 
Figure 2.3 Schematic of organic and inorganic drug delivery systems for cancer 
diagnosis and therapy [39]. 
 
The existing challenges of drug delivery system are to design suitable carriers that can 
efficiently encapsulate anticancer drugs, overcome drug-resistance, and increase 
selectivity of drugs towards cancer cells while eliminating their toxicity to normal tissues. 
To efficiently encapsulate drugs into a carrier, the selection of the carrier must be 
strongly based on the properties of the anti-cancer agents such as size, hydrophilicity, and 
other chemical properties. Moreover, the association between drugs and the carrier also 
determines the release rate of drugs inside the tumor cells. Once the drug-loaded carrier 
in the blood stream, the system is usually be taken up by liver, spleen and other parts of 
the reticuloendothelial (RES) system. The taken up rate of the system by RES depend on 
its surface properties. The more hydrophobic system is preferentially taken up by the 
liver, the spleen and lungs [40]. At the tumor level, the accumulation mechanism of the 
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drug-loaded carrier system relies on the diffusion or convection across the leaky tumor 
vasculature. As presented in Figure 2.4,  drug-loaded carriers with nano-size have higher 
accumulation into cancer tissues by the enhanced permeability and retention (EPR) effect 
due to the leaky blood vessels and the dysfunctional lymphatic drainage of tumors [41-
44]. The uptake of a drug delivery system can also be enhanced by decorating the carrier 
with specific ligands. In addition other important properties of carriers have also been 




Figure 2.4 Schematic of delivery mechanism of drug-loaded carriers to tumor cells [42, 
45].  
 
Compared with small-molecule drugs, the nanoparticulate drug delivery technology 
exhibits more favorable properties such as (1) prolonged systemic circulation, (2) 
sustained drug release, (3) higher accumulation into cancer tissues and (4) overcoming 
multiple drug resistance. Therefore, cancer chemotherapy using nanoparticulate drug 
delivery system has been expected to result in higher treatment efficacy with lower side-
effects. The first drug-loaded carrier (Doxil) was approved in 1995 using polyethylene 
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glycol (PEG) modified-liposome to encapsulate DOX. Doxil was designed with 100 nm 
size, hence it is delivered selectively to tumor tissues while excluding from the healthy 
tissues. By encapsulating DOX into nano-carriers, the serious side-effects caused by the 
toxicity of DOX have been reduced. As the result, the heart damage incidence of Doxil 
treated patients has been reduced by 3 times compared with that of traditional DOX 
treated patients [8].  
 
2.4 Common carriers for anticancer drug delivery 
2.4.1 Liposomes 
 
Figure 2.5 Schematic of drug-loaded liposome formation.  
 
Liposomes are hollow spherical vesicles made from amphiphilic phospholipid molecules. 
Liposomes are biocompatible and can be used for encapsulation of both hydrophobic and 
hydrophilic drugs due to their hydrophilic core and hydrophobic shell properties. The 
most widely studied form of liposomes is lipid bilayer vesicles with the size ranging from 
100 nm to 800 nm. Different preparation methods can produce liposomes with different 
sizes and characteristics. The most common and simple procedure for drug-loaded 
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liposome fabrication is the thin-film hydration method (Figure 2.5), in which the thin film 
of the mixture of lipids and drugs are hydrated with an aqueous solution.  
 
Table 2.2 Sample of some liposome-based drugs for cancer chemotherapy. 
Carrier*  Drug  Indication  Status/Name  Ref.  




 Daunorubicin Kaposi’s Sarcoma Approved/ 
Daunoxome 
[48] 











 Doxorubicin Stomach cancer Phase I/ MCCDDP-
465 
[52] 
 Irinotecan Advanced solid 
tumors  
Phase I/IHL-305 [53] 
Thermally sensitive 
PEG-modified 




FOL-PEG-modified  Doxorubicin Solid tumors In vitro [56-58] 
FOL/TMSP-PEG-
modified 
Docetaxel Solid tumors In vitro, in vivo [59] 
LHRH-PEG-modified Paclitaxel Non-small lung 
cancer  
In vitro, in vivo [60] 
Anti-CD30-PEG-
modified 
Doxorubicin Anaplastic large cell 
lymphoma 
In vitro, in vivo [61] 
TH-PEG-modified Paclitaxel Acidified tumors In vitro, in vivo [62] 
P18-4-PEG-modified Doxorubicin Breast cancer In vitro [63] 
* FOL: folate, TMSP: tumor microenvironment-sensitive polypeptides, LHRH: luteinizing 
hormone-releasing hormone TH (AGYLLGHINLHHLAHL(Aib)HHIL-NH2) 
 
The concept that liposomes could be used as drug delivery systems was established in 
1971 by Gregoriadis [64]. Many types of anticancer drug-loaded liposomes have been 
developed and some of them are listed in Table 2.2.  The initial drug-loaded liposomal 
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systems were developed based on non-modified liposomes. However, the short 
circulation time has been observed for these non-modified liposomal systems. Therefore, 
PEG was lately attached onto liposomes to increase their circulation time [65-67] and 
surface modification of liposomes with ligands was developed. Among them, many 
liposomal systems have been successfully developed for clinical use. Liposomes have 
been widely used for drug delivery in research and clinical trials due to their attractive 
properties such as biocompatible, able to encapsulate both hydrophilic and hydrophobic 
drugs, able to form highly homogeneous vesicles, able to modify the surface property. 
However, there are some limitations of using liposomal systems. The highly leakage of 
the lipid bilayers may lead to extravasation of toxic drugs in the healthy cells. Liposomes 
have low permeability to hydrophilic drugs but high permeability to hydrophobic drugs 
that leads to a problematic for the retention of highly hydrophobic drugs [68]. Other 
limitations are less sustained release property, fast oxidation of phospholipids and high 
production cost [42]. 
 
2.4.2 Polymer-drug conjugates 
Polymer-drug conjugates are another common approach for small anticancer drug 
delivery, which manipulate small anticancer agents to improve their cell specificity. 
Typically, a polymer-drug conjugate typically has tripartite structure: a polymer, a linker 
and an active agent. Lately, much more elaborate systems with additional of cell-specific 
targeting ligands and/or intracellular trafficking moieties provide the ability to effectively 
target [60, 69] and penetrate the diseased cells (Figure 2.6).  
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Figure 2.6 Schematic of drug delivery system using polymer-drug conjugate system [70]. 
 
Polymer-drug conjugates use specific water-soluble polymers as inert functional parts of 
conjugated systems to improve circulation time of the drugs and reduce their exposure to 
healthy cells. As shown in Table 2.3, various biocompatible polymers with a linear, 
random-coil structure have commonly been used to fabricate polymer-drug conjugates 
including PEG, hydroxypropylmethacrylamide (HPMA), poly(glutamic acid) (PGA), 
polyamidoamine (PAMAM). The most challenging part for designing an effective 
polymer-drug conjugate is the availability of a bio-responsive linker. The linker should 
be stable during transport of the system but able to release the drug at a designed rate at 
the targeted tumor.  Peptide linkers have been popularized by the successful design of 
HPMA-GFLG-doxorubicin conjugates. This GFLG tetrapeptide linker is stable in the 
blood circulation but is cleaved in the cell by the liposomal thiol-dependent protease 
cathepsin B [70]. Other linkers such as cis-aconityl, hydrazone and acetal have also been 
used as an alternative for polymer-drug conjugates.  In addition,  the system can easily be 
precipitated in vivo due to the high and localized concentration of hydrophobic drug 
molecules bound along the polymer chain [71-73]. Therefore, drug-polymer conjugates 
must be designed with considerable low drug content to avoid precipitation. Moreover, 
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the system can easily accumulate in the glomeruli of kidneys and be quickly cleared due 
to their small size of 5-15 nm. 
 
Table 2.3 Sample of polymer-drug conjugates. 
Polymer*  Drug**  Indication Status/Name  Ref.  
PGA Camptothecin Advanced solid tumors Phase I/ C TAM- 
2106 
[74-76] 
 Paclitaxel Lung cancer 
 
Advanced solid tumors 




PEG Asparaginase Leukemia Approved/ 
Oncaspar 
[80] 
HPMA DACH-Pt Ovarian cancer Phase II/AP5346 [81-84] 
 Doxorubicin Breast, lung, colorectal 
cancers 
Phase II/PK1 [37, 85] 
MSH-HPMA Doxorubicin Murine melanoma In vitro, in vivo [69] 
LHRH-modified (PEG) Paclitaxel Non-small lung cancer  In vitro, in vivo [60] 
LHRH-modified 
(PAMAM) 
Paclitaxel Non-small lung cancer  In vitro, in vivo [60] 
* MSH: melanocyre-stimulating hormone  
**DACH-Pt: 1,2-diaminocyclohexane-platium  
 
2.4.3 Polymeric nanoparticles (NPs) 
Polymeric nanoparticles (NPs) are spherical structures with various sizes ranging from 
100 nm up to micron-size depended on the molecular weight of the polymers. Polymeric 
NPs can be used to delivery different types of anticancer drugs via physical interactions 
or chemical bonds (Figure 2.7) between drugs and polymers. The chemical bonds 
between drug and NP allow a delay in the release of drug until the nanoparticles reach the 
targeted delivery site. In addition, larger amount of drug can also be chemically loaded 
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into the NP. However, the alteration of drug activity after the conjugation is a drawback 
of the polymer-drug conjugated NPs for practical application.  
 
Figure 2.7 Schematic of polymer-drug conjugate nanoparticles [86].  
 
As shown in Table 2.4, many polymers or copolymers have been used for fabricating 
carriers for drug delivery systems. In the early stage, most of studies are based 
biodegradability, biocompatibility [34, 87-89] polymers/copolymers including poly(D,L-
lactide) (PLA) and poly(D,L-lactide-co-glycolide) (PLGA), PEG-PLGA,  PEG-PCL, 
PEG-PEI. Subsequently, drug-loaded NPs have been further developed by attaching 
ligands on their surface to improve the treatment efficacy. However, only few systems 
have been approved for clinical trials such as abumin-based and cyclodextrin-PEG 
systems for delivery of paclitaxel and captothecin, respectively. The clinical application 








Table 2.4 Nanoparticle-based drugs for cancer chemotherapy [31, 86]. 
Carrier*  Drug  Indication  Status/Name  Ref.  
Abumin-based Paclitaxel Breast cancer Approved/Abraxane [90] 
PLGA Paclitaxel, 
etanidazole 
Solid tumors In vitro [91, 92] 
Nanoparticles Docetaxel Solid tumors Phase I/Docetaxel-
PNP 
[31] 
Cyclodextrin-PEG Captothecin Gastric cancer Phase II/CRLX101 [93-95] 
PEG-PLGA Doxorubicin, 
paclitaxel 
Solid tumors In vitro, in vivo [96, 97] 
FOL-TPGS/TPGS-PLGA Doxorubicin Solid tumors In vitro [87] 
FOL- TPGS-PLA Paclitaxel Solid tumors In vitro [98] 
Trastuzumab-modified 
PLGA-MMT 
Paclitaxel  Breast cancer In vitro [99] 
TAT-PEG-PEI Doxorubicin/ 
DNA 
Solid tumors In vitro [100] 
APT-PEG-PEI Doxorubicin/ 
Bcl-xL shRNA 
Prostate In vitro [101] 
CGKRK peptide-PEG-PCL Paclitaxel Solid tumors In vitro, in vivo [102] 
Anti-CD 133-PLGA Paclitaxel Breast Cancer In vitro, in vivo [103] 
* TPGS: tocopheryl polyethylene glycol succinate, APT: anti-PSMA aptamer, PEI: 
poly(ethyleneimine) 
 
2.4.4 Polymeric micelles 
Polymeric micelles are typically formed by self assembly of amphiphilic polymers which 
have hydrophobic blocks and hydrophilic blocks. In the aqueous medium, micelles are 
formed with a hydrophobic core and a hydrophilic shell structures at the concentration 
above their critical micelle concentrations (CMC), through hydrophobic interactions 
between the hydrophobic segments of the polymer, as well as through solvation and steric 
repulsion among the hydrophilic segments of the polymer. Polymeric micelles have been 
using as anticancer drug carriers based on various interactions between the drugs and 
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core of micelles such as the hydrophobic, electrostatic, π-π interactions, hydrogen or 
covalent bondings.  
 
Figure 2.8 Schematic of preparation of physical drug-loaded polymeric micelles. 
 
Drug-loaded micelles can be prepared by two methods as shown in Figure 2.8. In direct 
self-assembly method, the amphiphilic copolymer and the drug are directly solubilized in 
an aqueous medium at a concentration above its CMC. In contrast, in dialysis method, 
both copolymer and drug are firstly dissolved in an organic medium. Subsequently, the 
resulting drug-polymer solution is subjected to solvent exchange against aqueous phase 
via dialysis method to induce the micelle formation. The fabrication method is generally 
selected based on the building blocks of the micelle system and the drug properties. The 
more water soluble amphiphilic copolymers and drugs are generally fabricated into 
micelles via the former direct dissolution method. On the other hand, the highly 
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hydrophobic drugs and poor water soluble copolymers with strong hydrophobic tails are 
usually fabricated into micellar forms through the dialysis method.  
 
For cancer therapeutic applications, the micelle vehicle should have low toxicity, low 
immunologic response, as well as low CMC to ensure stable particulate-delivery system 
under huge extent of dilution by blood upon intravenous injection to the host organism. 
In micellar drug delivery systems, the hydrophobic core of micelles can act as a reservoir 
for hydrophobic drugs, while the hydrophilic shell protects the micelle from the 
macrophage recognition and determines its circulation time. Polyethylene glycol (PEG) 
has been proven as a material that can increase the circulation time of particles and 
provide better protection to particles from liver uptake and plasma protein adsorption 
[104]. Therefore, PEG is the most popular used corona-forming polymer currently with a 
molecular range from 2 to 15 kDa (Table 2.5). Core-forming blocks can consist of 
various polymer blocks such as poly(D,L-lactide-co-glycolide) (PLGA), poly(D,L-
lactide) (PLA), poly(glutamic acid) (PGA), poly(asparate) (PAsp), polyaspartate 
modified with 4-phenyl-butanol (PAPB), poly(carbonate-co-lactide) (P(CB-co-LA)), 
phosphatidylethanolamine (PE), poly(l-lactide-co-2-methyl-2-carboxyl-propylene 
carbonate) (P(LA-co-MCC)), poly (L-cystine bisamine-g-sulfadiazine) (PCBS), poly(ε-
caprolactone) (PCL), acid-functionalized polycarbonate (PAC), urea-functionalized 
polycarbonate (PUC). The selection of core forming blocks is based on the nature 
structure and functional property of the encapsulated drugs. Polymeric micelles have 
commonly been used for delivering hydrophobic or amphiphilic drugs, they may also be 
used to encapsulate several hydrophilic drugs by using polymers that exhibit specific 
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interactions with the drugs such as formation of complexation [105-108], or electrostatic 
[109]. Typically, the amphiphilic copolymers with hydrophilic-lipophilic balance (HLB) 
values between 5 and 19 are used to form micelles for drug delivery. When the HBL 
value gets closer to 0 (hydrophobic extreme), the CMC value is reduced. The micelle 
with lower CMC value is more desirable for drug delivery system because the stability of 
the system upon dilution by the blood is increased.   However, copolymers with low HBL 
values may lead to the less hydrophilic micelles which cause the fast aggregation and 
clearance from the bloodstream. Therefore, many researches are still on going to further 
optimize the more suitable polymeric micelles for drug delivery system. 
 
Table 2.5 Drug-loaded polymeric micellar formulations. 
Carrier*  Drug  Indication  Status/Name  Ref.  
PEG-PLGA Doxorubicin Solid tumors In vitro [110] 
PEG-PLA  Paclitaxel  
 
Breast, lung and 





PEG-PGA DACHPt Orthotopic 
scirrhous gastric 
In vitro,  in vivo [107, 
108] 






 SN-38  Breast cancer  Phase II/ NK012 [115, 
116] 
PEG-PAsp  Doxorubicin  Pancreatic and 
colorectal cancers  
Phase II/ NK911 [117] 















Breast cancer In vitro [124] 





PEG-PAC/PEG-PUC Doxorubicin Solid tumors In vitro, in vivo [127] 
PEG-P(CB-co-LA)/PEG-PLA Bicalutamide Prostate cancer In vitro [128] 
pH-sensitive PEG-PDPA Chlorin e6 Lung cancer  In vitro [129] 
pH-sensitive PAE-g-ADPC Doxorubicin Solid tumors In vitro [130] 
Anti-VEGF- PEG-PAsp Adriamycin Liver tumor In vitro, in vivo [131] 
FOL-modified (PEG-PLGA) Doxorubicin Solid tumors In vitro [132] 
FOL-modified (PEG-PAE) Doxorubicin Solid tumors In vitro [133] 
FOL-modified (PEOz-PCL) Doxorubicin Solid tumors In vitro, in vivo [134] 
ACUPA-modified (PEG-PLA 
or PEG-PLGA) 





A10-modified (PEG-PLA) Doxorubicin prostate cancer In vitro, in vivo [136] 
TAT-modified (PEG-PE) Paclitaxel Solid tumors In vitro, in vivo [137] 
TAT-modified (PEG-
Cholesterol) 




Daunorubicin Solid tumors In vitro [140] 
TAT-modified (PEG-
PLA/PCBS-PEG) 
Doxorubicin Acidic solid 
tumors 
In vitro [141] 




Currently, polymeric micelles are popular pharmaceutical carriers for the delivery of 
anticancer drugs due to their advantages over other systems [142]. They are small size 
with a narrow distribution that is considered ideal for stable and long term circulation in 
the blood stream because it evades the RES uptake. Moreover, while remaining stable in 
the blood over a long time period, the carriers are small enough to pass through small 
blood vessel pores of less than 400 nm [143]. From this point of view, polymeric micelles 
are an effective delivery system in term of the enhanced permeability and retention (EPR) 
effect and overcoming the RES system [9]. The second advantage is the high static and 
dynamic structural stability [144, 145]. Static stability is described by a CMC. Dynamic 
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stability is described by the low dissociation rates of micelles. The high structural 
stability of polymeric micelles provides sustainable delivery of drug in vivo because the 
shape and structure of the micelles can be maintained upon injection into the patient’s 
body. The third advantage is the high solubility of micelles in aqueous media. Due to the 
encapsulation of anticancer drugs in the core of polymeric micelles, the precipitation of 
drug in vivo can be prevented by utilizing a hydrophilic outer shell layer that works as a 
barrier against the inter-micellar aggregation. The fourth advantage is that the system can 
be modified easily to change the size, surface property and also the interaction with 
drugs.  
 
Figure 2.9 Schematic of BIND-014, a docetaxel (DTXL)-loaded micelle system with 
small-molecule (ACUPA) targeting ligands.  
 
As the application of polymeric micelle system in cancer drug therapy becomes very 
appealing owing to its suitable characteristics as drug carrier, some drug-load micellar 
systems have been reached to clinical phases or even  been approved for clinical use as 
shown in Table 2.5. Generxol-PM is a paclitaxel-loaded micellar system that has been 
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approved for the treatments of breast, lung and ovarian cancer [111, 112]. Other drugs-
loaded micellar systems have been approved for clinical trials such as the delivery of 
doxorubicin [117, 125, 126], cisplatin [106, 114], SN-38 [115, 116]. Specially, BIND-
014 is the first active targeted drug-loaded nano-system that has been approved for phase 
I human clinical trial [135].  BIND-014 is a targeted micellar system using amphiphilic 
polymers poly(D,L-lactide)-poly(ethylenglycol) (PLA-PEG) or  poly(D,L-lactide-co-
glycolide)-PEG with small-molecule (ACUPA) targeting ligands to physically 
encapsulate docetaxel (DTXL) (Figure 2.9) for the treatment of advanced solid tumors. 
 
2.5 Overview of current drug delivery strategies 
Traditional cancer treatments often kill healthy cells and cause toxicity to the patient. 
Therefore, it would be desirable to develop chemotherapeutics that can either passively or 
actively target cancerous cells. Passive targeting exploits the characteristic feature of 
tumor biology that allows carriers to accumulate in the tumor by the enhanced 
permeability and retention (EPR) effect. Active approaches achieve this by conjugating 
carriers containing chemotherapeutics with molecules that bind to overexpressed antigens 




Figure 2.10 Schematic of multifunctional polymeric carriers for active drug delivery 
[24]. 
 
2.5.1 Passive delivery 
General features of tumors include leaky blood vessels and poor lymphatic drainage. 
Whereas free drugs may diffuse nonspecifically, a drug carrier can escape into the tumor 
tissues via the leaky vessels by the EPR effect (Fig. 2.11). The increased permeability of 
the blood vessels in tumors is characteristic of rapid and defective angiogenesis 
(formation of new blood vessels from existing ones). Furthermore, the dysfunctional 
lymphatic drainage in tumors retains the accumulated drug carriers and allows them to 
release drugs into the vicinity of the tumor cells. Although passive targeting approaches 
form the basis of clinical therapy, they suffer from several limitations. Ubiquitously 
targeting cells within a tumor is not always feasible because some drugs cannot diffuse 
efficiently and the random nature of the approach makes it difficult to control the process. 
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This lack of control may induce multiple-drug resistance (MDR). MDR occurs because 
transporter proteins that expel drugs from cells are over-expressed on the surface of 
cancer cells. The passive strategy is further limited because certain tumors do not exhibit 
the EPR effect, and the permeability of vessels may not be the same throughout a single 
tumor. The same phenomenon has been observed from the cancer treatment using Doxil 
in clinical. The treatment results show that Doxil fails to penetrate deeply into the tumor 
that results in the lesser efficacy compared to the traditional DOX [8]. 
 
 
Figure 2.11 Schematic of a passive targeted drug delivery system [31]. 
 
2.5.2 Active delivery by targeting to cancer cells 
To overcome the limitations of passive delivery, the drug-loaded carriers should be 
modified with molecules that bind to over-expressed antigens or receptor on the cancer 
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cells. This selective binding can be achieved by attaching targeting agents, such as 
ligands, to the surface of the carrier. Due to the high interaction between the ligands and 
receptors on cancer cell surface and the over-expressed on the receptors on cancer cells 
but lack of that on healthy cells, the drug-loaded carriers actively bind to cancer cells 
through ligand–receptor interaction while bypassing the healthy cells. The bound carriers 
are internalized, and the drug is released inside the cell (Figure 2.12).  
 
 
Figure 2.12 Active drug targeting to cancer cells due to the high binding affinity between 
the targeting moiety on the drug-carrier surface and the over-expressed receptors on the 
tumor cell membrane [86]. 
 
Cancer cell targeting ligands are classified as protein (mAb, Fab, F(ab’)2, scFv), 
aptamers, vitamins (folate, biotin), peptides and other ligands (transferrin, hyaluronan). 
One of the common ligands for cancer cell targeting is folate that required by all 
eukaryotic cells for 1-carbon metabolism and de novo nucleotide synthesis. Folate 
receptor (FR) expression has been detected at very high levels in >90% of ovarian and 
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other gynecological cancers, and at high to moderate levels in brain, lung, and breast 
carcinomas [146-148]. The fact that FRs bind to folate-conjugated carriers with high 
affinity (10-9 M) and that the carriers are subsequently transported nondestructively into 
the target cells only adds to the utility of this strategy for tumor-specific drug [149].  
 
2.5.3 Active delivery by targeting to endothelial cells  
Receptors expressed on the apical surfaces of epithelial cells often constitute good 
targets, since these receptors in normal epithelia are inaccessible to parenterally 
administered drugs. The drug-loaded endothelial cell targeted carriers have been designed 
by modification the carrier surface with ligands that can target to the endothelial over-
expressed receptors (Figure 2.13). Antibody fragment L19 [150, 151] and derivaties of 
oligoopeptides RGD [152, 153] and NGR [154] have been used as ligands for carrier 
modification to target endothelial cells.  
 
Figure 2.13 Active drug targeting to receptors over-expressed on endothelial cells [31]. 
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2.5.4 Cell-penetrating peptides  
Cell-penetrating peptides (CPPs) correspond to the number of known natural and 
synthetic short peptides of less than 30 amino acids with cell-penetrating capabilities. 
Many short peptides have been identified as CPPs based on their ability of transporting 
diverse types of carriers. Table shows some frequently used CPPs for the transport of 
various carriers. Among them, TAT peptide, the HIV1-derived trans-activator of 
transcription peptide, is one of the most intensively studied CPPs that was firstly 
investigated by Green [155] and Frankel in 1988 [156]. The increase cellular uptake of 
different TAT sequences has been demonstrated by researchers as shown in Table 2.6.  
Different TAT sequences such as YGRKKRRQRRR, GRKKRRQRRR, RKKRRQRRR, 
GRKKRRQRRPPQ, GGYGRKKRRQRRR have been proven as cell-penetrating moieties 
which can enhance the penetrating of the TAT-modified carriers into the cells. 
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Table 2.6  Representative CPPs and their applications. 
CPPs Sequences Carrier types  Ref. 
TAT47-57 YGRKKRRQRRR Micelle, liposome, nanoparticle, plasmid, polymeric 
liposome 
[139, 157-165] 
TAT48-57 GRKKRRQRRR Nanoparticle [166] 
TAT49-57 RKKRRQRRR Protein, nanoparticles [167, 168] 
TAT48-60 GRKKRRQRRPPQ siRNA, protein, peptide, liposome, nanoparticle [169-172] 
TAT GCGGGYGRKKRRQRRR Micelle, nanoparticle [141, 173, 174] 
TAT GGYGRKKRRQRRR Micelle, nanoparticle [175] 
Penetratin RQIKIWFQNRRMKWKK Peptide, siRNA, liposome [176] 
Transportan GWTLNSAGYLLGKINLKALAALAKKIL Protein  [177] 
MPG GALFLGFLGAAGSTMGAWSQPKKKRKV Plasmid, siRNA [178] 
Pep-1 KETWWETWWTEWSQPKKKRKV Protein, peptide [179] 
MAP KLALKLALKALKAALKLA Protein [180] 
SAP VRLPPPVRLPPPVRLPPP Protein, peptide [181] 
SynB RGGRLSYSRRRFSTSTGR Doxorubicin [182] 
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In drug delivery field, CPPs have been proven effective at increasing the treatment 
efficacy of therapeutics by improving cellular uptake with lower toxicity and more 
controlled administration than other delivery vectors [183-185]. CPPs have been 
conjugated to a variety of therapeutics including small molecules [182, 186-190], 
proteins [191-194], antibodies [195], nucleic acids [196-198], liposomes [158, 199, 200], 
micelles [137, 157, 201, 202] or nanoparticles [159, 203-205] to trigger the transportation 
of therapeutics across the cell membrane into the cytoplasm of cells.  
 
 
Figure 2.14 Model of cellular uptake and intracellular trafficking of CPPs. CPP-carriers 




Although cellular internalization of CPPs has been observed in various cell types, their 
mechanism of activity has not yet completely elucidated. It is proposed that CPP-
conjugated small-sized carrier cross cells via (1) membrane fusion or (2) endocytosis 
pathway (caveolin-dependent, clathrin-dependent, clathrin- and caveolin-independent) 
[206-208], while CPP-conjugated large-sized carrier enter cells via (3) macropinocytosis 
[194, 206, 209] as shown in Figure.  It seems that there might be multiple mechanisms in 
cellular uptake of CPP-conjugated carriers depending on the nature of CPPs, the size and 
nature of carriers, cell membrane composition, physiological state of the cells [176, 210, 
211]. 
 
2.6 Combination chemotherapy 
2.6.1 Overview of combination chemotherapy 
Single agent therapy has seen limited success in cancer treatment due to the toxicity at 
high drug dosage, the heterogeneity of cancer cells and the drug resistance [212-215]. 
Recently, a variety of different types of combination therapy, which involves the 
administration of different classes of chemotherapeutics to a patient, has been used for 
cancer treatments to maximize cancer therapeutic efficacy while minimizing toxicity. 
Many studies have demonstrated that the combination chemotherapy can exhibit better 
cancer treatment efficacy while having lower MDR effect in various types of cancer 
diseases such as breast cancer [216-218], lung cancer [219], ovarian adenocarcinoma 
[214], synovial sarcoma, osteosarcoma and uterine  leiomyosarcoma [215].  Some 
combinations have also been shown clinically to treat cancer disease more effectively in 
comparison to the administration of a single agent as shown in Table 2.7. 
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Table 2.7 Synergistic combinations in clinic [220]. 
 
 
2.6.2 Principle of drug selection in the combination  
The effects of combinations of drugs are enhanced when the combined therapy provides a 
synergistic effect. To obtain a synergistic effect, the drugs in the combination treatment 
generally has to be chosen following the principles such as (i) using drugs with non-
overlapping toxicities  so that each drug in the combination can be administered at near 
maximal dose, (ii) combining drugs with different mechanisms of action so that multiple 
sites in biochemical pathways can be attacked thus resulting in synergy, and (iii) 
combining drugs that exhibit synergistic effect against cancer cells, or additive antitumor 




Figure 2.15 Cell cycle phases [221]. 
 
Based on the above principles, drugs in a combination should firstly exhibit different 
pharmacological effects. Because most of anticancer drugs are cell cycle specific, the cell 
cycle of drugs in a combination is another rational target to enhance the treatment 
efficacy. As shown in Figure 2.15, a single parent cell divides into two identical daughter 
cells through a cell cycle that includes several phases including G1, S, G2, and M. G1 
(Gap 1) is a growth phase in which proteins and enzymes that are required in S phase are 
formed. Subsequently, the cell enters the S (Synthesis) phase. During this phase, the 
DNA duplication occurs, that is the most basic function of the cell cycle. After S phase, 
the cell enters the G2 phase, where repair might occur along with preparation for mitosis 
in M (Mitosis) phase. In M phase, the nuclear envelope breaks down, microtubules attach 
to the chromosome’s kinetochores aligning them at the mitotic spindle’s equator. After M 
phase, the cell enters G1or G0 (quiescent phase).  
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2.6.3 Some commonly used anticancer drugs and their combinations  
Many types of anticancer drugs which have distinct mechanisms of action have been 
investigated and clinically used. For the purpose of this thesis, the discussion is focused 
on the mechanisms of action of four anticancer drugs (Figure 2.16) and their 
combinations (doxorubicin+paclitaxel, paclitaxel+tamoxifen, and doxorubicin+cisplatin).   
 
Figure 2.16 Molecular structures of (A) doxorubicin, (B) paclitaxel, (C) tamoxifen, and 
(D) cisplatin. 
 
Doxorubicin (DOX) is one of the most potent and widely cytotoxic chemotherapeutic 
agents with a significant and use-limiting-side-effect profile. DOX is an anthracycline 
antibiotic that works by inhibiting the synthesis of nucleic acids within cancer cells and 
exhibits the most effective in treating the cancer cells in the S phase. It is a very powerful 
chemo-drug for treatment of some leukemias, hodgkin’s lymphoma, as well as cancers of 
the bladder, breast, stomach, lung, ovaries, thyroid, soft tissue sarcoma, multiple 
myeloma, etc. However, DOX also has a number of undesirable side effects such as 
cardiotoxicity and myelosuppression which leads to a very narrow therapeutic index. 
 
Paclitaxel (PTX) is an effective mimotic inhibitor anticancer agent that can block cell 
cycle in G2 and M phase. PTX, a microtubule-stabilizing agent, promotes polymerization 
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of tubululin causing cell death by disrupting the dynamics necessary for cell division. It 
has neoplastic activity especially against primary epithelial ovarian carcinoma, breast, 
colon, and non-small cell lung cancers. PTX therapeutic efficacy is limited by its poor 
aqueous solubility. In addition, systemic administration of PTX is also associated with 
several side effects such as dyspnea, hypotention, nephrotoxicity and neurotoxicity. 
 
Tamoxifen (TAM) is the most commonly used therapeutic agent for the treatment of 
estrogen receptor-possitive breast cancer. It is a hormonal drug that acts as an anti-
estrogen by binding to the estrogen receptor but do not activate it. Because of this 
competitive antagonism, TAM interferes with the body’s ability to make estrogen by 
blocking the activity of aromatase, an enzyme needed for the final steps of estrogen 
production. TAM is effective in blocking cell cycle progression on G0, G1 and early S 
phase. Besides the promising success rates of TAM in cancer treatment, it also has 
estrogenic effects in the uterus and other side effects including endometrial cancer, fatty 
liver, pulmonary emboli, venous thrombosis, reduced cognition and ocular side effects.  
 
Cisplatin (CDDP) is an alkylating agent that has activity in many different cancer 
diseases such as testicular, ovarian, lung, bladder, testicular, head and neck cancers. 
CDDP inhibits tumor growth by binding with DNA to form adducts and intrastrand 
cross-links that change the conformation of the DNA and inhibit DNA replication. 
Although CDDP functions as a non-cell cycle specific, cancer cells appear to be 
maximally sensitive to CDDP in G1 phase. CDDP causes some severe side effects 
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including nausea, vomiting, bone marrow effects, significant renal dysfunction, and 
acoustic nerve dysfunction. 
 
The two drugs in (DOX+PTX), (PTX+TAM) or (DOX+CDDP) combinations have 
different mechanisms of actions and non-overlapping toxicities. Therefore, these 
combinations may exhibit synergistic effect in cancer therapy. Because the effect of the 
combination strongly influenced by the combination ratios, combinations at different 
fixed drug ratios are evaluated to define the optimum ratio(s) which exhibit(s) synergistic 
effect. 
 
2.6.4 Determination of combined chemotherapeutic effect 
Evaluation of drug interactions in combinations is conducted in vitro by a series of 
concentrations (Figure 2.17A) to obtain dose response curves (Figure 2.17B) for the 
drugs and combinations. After that, the drug interactions of combinations are assessed as 
shown in Figure 2.17C. Briefly, individual drugs are firstly screened separately in vitro 
assay(s) to determine their individual activities. Then, pairs of drugs at different fixed 
ratios are combined and assayed in the same condition. Cell growth or cell viability are 
measured using a variety of cytotoxicity assays such as 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay [222], trypan blue [223], glutamate pyruvate 
transaminase (GPT) assay, lactate dehydrogenase (LDH) assay [224], propidium iodide 
staining [225], clonogenic assays [226], mitochondrial membrane potential (MMP) assay 
[227], sodium 3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium)-bis-(4-methoxy-6-nitro) 
benzene sulphonic acid hydrate (XTT), 3-(4,5-dimethylthiazol-2-yl)-5-(3-
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carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium (MST) [228]. MTT assay is 
preferred for in vitro cytotoxicity study because it is very robust and is metabolised by 
most cell types. However, it is recommended to apply for than one assay to confirm the 
results of individual assays when detailed information is required [228]. 
 
Figure 2.17 In vitro evaluation of synergistic drug interactions [229]. 
 
Combination effects over concentration ranges of combined ratios may be determined 
using various available mathematical algorithms such as Isobologram methods [230, 
231], the fractional product method, Chou and Talalay median-effect method [232, 233]. 
Chou-Talalay median-effect method has been widely used for determination of 
combination effects because it can provide similar accuracy compared to other methods 
while requires lesser number of measurements. The analysis utilizes the dose-effect 
equation:  
𝑙𝑜𝑔(𝑓𝑎 𝑓𝑢⁄ ) = 𝑚𝑙𝑜𝑔(𝐷) −𝑚𝑙𝑜𝑔                                                                                         (2 − 1) 
where fa and fu are the fraction affected and unaffected by the dose respectively, Dose is 
the dose of the drug used, and Dosem is the median-effect dose signifying the potency. 
This equation is further manipulated to calculate the combination index (CI) of the 
combined two drugs (eq. 2-2) based on additive effect of the two drug-effect equation 
from Loewe additivity model:  
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𝐶𝐼 = (𝐷𝑜𝑠𝑒)1(𝐷𝑜𝑠𝑒𝑥)1 +  (𝐷𝑜𝑠𝑒)2(𝐷𝑜𝑠𝑒𝑥)2                                                                                                 (2− 2) 
where (Dose)1 and (Dose)2 were the dose of drug 1 and drug 2 in the combination that 
kill x% cells, (Dosex)1 and (Dosex)2 were the dose of drug 1 and drug 2 in single drug 
treatment to kill x% cells. 
The interaction of the two drugs can be classified as synergistic (CI < 1), additive (CI = 
1) or antagonistic (CI > 1) (Figure 2.20C) based on the fraction affected or cell viability 
data [219]. 
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CHAPTER 3.  Surface modification of polymeric micelle 
particles for enhancement of cancer targeting and penetrating 
ability 
 
3.1 Introduction  
The use of polymeric micelles as drug carriers started in the 1980s by Bader et al. [234, 
235], and these class of carriers started to be known to improve drug delivery efficiency 
in the 1990s [236, 237]. From 1990s until recent years, micelles have further investigated 
to explore more about their biological and medicinal uses in cancer treatment [128, 139, 
238]. Several polymeric micelle carriers have been evaluated in clinical trials and they 
have been found to be a potential type of drug carrier system [122, 239-242]. The unique 
features that have made polymeric micelles attractive are small size, biodegradability and 
high flexibility for structural and chemical modification [243].  
 
Early generation of polymeric micelles simply entered tumors by passive targeting and 
may not deliver sufficiently high concentration of anticancer drugs inside the cancer cells 
[110]. Therefore, polymeric micelles with surface modification targeting cancer cells 
specifically and being able to across the plasma membrane of cells efficiently may offer 
new opportunities in the area of cancer therapy. However, efficient drug transportation 
through the plasma membrane still remains a major hurdle for drug delivery [244]. 
Improving the transport process across the plasma membrane significantly reduces the 
amount of administered drug, and the side effects on healthy tissues.  
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A family of positively charged short peptides, known as cell-penetrating peptides (CPPs), 
was identified in mid-1990s [245]. CPPs are considering as promising candidates for 
drug delivery since they are capable of transporting attached macromolecules from 
extracellular space through the cell membrane into cytoplasm in both in vitro and in vivo 
studies [138, 159, 172, 246]. One of the CPPs receiving great attention is TAT peptide, a 
cationic peptide derived from the human immunodeficiency virus type 1 (HIV-1) [247]. 
Many studies have used TAT to transport intracellular cargoes, such as DNA [248], 
quantum dots, polymers [249], micelles [138, 141], nanoparticles [159] and liposomes 
[250]. Moreover, the TAT peptide has been shown to exhibit no toxicity to many cells, 
such as to Hela and Jurkat cells with the concentration of up to 20-30 µM [251] and to 
lymphocytes up to 300 µM [252]. 
 
Although highly efficient for in vitro cellular uptake, in vivo application of CPPs is much 
more complicated. The main reason is the lack of cell specificity, thus limiting the 
clinical application of CPP-mediated delivery systems. Dowdy et al. showed that after 
intraperitoneal injection, CPP were found in the lung, liver, kidney, brain and other 
tissues [172]. To achieve high efficiency of tumor-specific drug delivery, it is important 
to modify the delivery carriers with a ligand that is able to target to specific cancer cells 
of interest. Folate (FOL) is a targeting ligand having high binding affinity to folate 
receptors overexpressed in ovarian, breast, brain, lung, colorectal cancer cells [253-255] 
and has widely been used to modify many delivery carriers such as nanoparticles [87], 
liposomes [256], micelles [257-260]. 
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In this study, to enhance efficient delivery of anticancer drug into cancer cells, we have 
developed a novel hydrophobic drug delivery system based on polymeric micelles with 
multifunctional surface properties as shown in Figure 3.1.  
 
Figure 3.1 Schematic of the drug-loaded multi-functionalized polymeric micelle that is 
investigated in this study. 
 
Mixed polymeric micelles based on PLGA-PEG, PLGA-PEG-FOL and PLGA-PEG-TAT 
copolymers were fabricated to encapsulate DOX (hydrophobic form), a model drug in 
this study. Micellar properties such as the critical micelle concentration (CMC), size, zeta 
potential, drug loading content and in vitro release were investigated. Furthermore, 
cytotoxicity study of DOX-loaded polymeric micelles was performed using human oral 
cavity carcinoma (KB) cell line. Finally, the cellular uptake efficiency of different 
micelles was evaluated using laser scanning confocal microscopy. 
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3.2 Experimental section 
3.2.1 Materials 
Poly(ethylene glycol) bis(amine) (PEG-diamine, Mw:10,000), poly(ethylene glycol) 2-
aminoethyl ether acetic acid (NH2-PEG-COOH, Mw: 10,000) were purchased from 
Laysan Bio Inc (USA). 75:25 poly(D, L-lactide-co-glycolide) with carboxylic end group 
(PLGA, Mw: 5,600) was acquired from Lakeshore Biomaterials (USA). TAT peptide of 
the sequence NH2-Tyr(tBu)-Gly-Arg(Pbf)-Lys(Boc)-Lys(Boc)-Arg(Pnf)-Arg(Pbf)-
Gln(Trt)-Arg(Pbf)-Arg(Pbf)-Arg(Pbf) (NH2-YGRKKRRQRRR) was custom-synthesized 
by GL Biochem (Shanghai) Ltd (China). Poly(ethylene glycol)-amine (PEG-amine, Mw: 
5,000), N-hydroxysuccinimide (NHS), dicyclohexylcarbodiimide (DCC), folic acid, 
pyridine, dichloromethane (DCM), N,N-dimethylformamide (DMF), dimethyl sulfoxide 
(DMSO) and triethylamine (TEA), trifluoroacetic acid (TFA), triiso-propysilane (TIS), 
coumarin 6 (C6), 3-[4,5-dimethylthiazolyl-2]-2,5-diphenyl tetrazolium bromide (MTT), 
ninhydrin kit were all purchased from Sigma-Aldrich (USA). Doxorubicin (DOX) was 
obtained from Boryung (Korea). Methanol, acetonitrile (ACN), tetrahydrofuran (THF), 
chloroform, diethyl ether were purchased from Tedia (USA). Folate-free RPMI 1640 
medium, fetal bovine serum (FBS), Trypsin-EDTA and penicillin-streptomycin were 
obtained from Invitrogen (USA). KB human oral cavity carcinoma cell line was 
purchased from ATCC (USA). Reagent graded water was obtained from the Milli-Q Plus 




3.2.2 Synthesis of PLGA-PEG 
PLGA-PEG block co-polymer was synthesized by the previously reported method with a 
slight modification [257]. Briefly, PLGA dissolved in DCM was activated by DCC and 
NHS at room temperature under N2 atmosphere for 24 h. The resultant solution was 
filtered and precipitated by dropping into ice-cold diethyl ether, followed by completely 
drying under vacuum for 2 days. The activated PLGA and PEG-amine (molar ratio of 
activated PLGA:PEG-amine = 1:1.2) dissolved in DCM were allowed to react at room 
temperature under N2 atmosphere for 3 h. The resultant solution was precipitated by 
dropping into ice-cold diethyl ether. The precipitated product, PLGA-PEG was dissolved 
in DMSO and dialyzed against de-ionized (DI) water for 2 days (MWCO: 10,000), and 
was further centrifuged to remove impurity and obtain PLGA-PEG. The product was 
freeze-dried in a freeze drier for 2 days. 
 
3.2.3 Synthesis of PLGA-PEG-FOL 
The synthesis of PLGA-PEG-FOL followed a 3-step reaction [257]– PLGA activation (as 
mentioned in the previous section), FOL capping to form PEG-FOL, and conjugation of 
PLGA with PEG-FOL to form PLGA-PEG-FOL. PEG-FOL was first synthesized by 
reacting PEG-diamine (Mw: 10,000) with folic acid and DCC/NHS (molar ratio of PEG-
diamine:folic acid:DCC:NHS = 1:1:2:2) in DMSO in the presence of pyridine. The 
reaction was carried out for 10 h in the dark at room temperature under N2 atmosphere. 
The mixture was then diluted with DI water and centrifuged to remove the insoluble by-
product dicyclohexylurea (DCU). The supernatant was further filtered to obtain clear 
yellow solution. The solution was dialyzed against DI water for 2 days (MWCO: 1000) to 
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remove DMSO and unreacted folic acid in the mixture and freeze-dried. The trace 
amount of unreacted PEG-diamine was then removed by batch adsorption with cellulose 
phosphate cation exchange resin using 5 mM phosphate buffer pH 7.0 as start buffer. 
PEG-FOL was further purified by a DEAE sephadex anion exchange column with 20 
mM Tris-HCl pH 8.0 as start buffer to remove FOL-PEG-FOL side product. The reaction 
of activated PLGA and PEG-FOL (molar ratio of activated PLGA:PEG-FOL = 1:1.2) 
was carried out for 8 h in DMSO at room temperature under N2 atmosphere. The product 
was precipitated twice in ice-cold diethyl ether, dissolved in DMSO for dialysis against 
DI water for 2 days (MWCO: 10,000), centrifuged to remove unconjugated PLGA, and 
then freeze-dried. 
 
3.2.4 Synthesis of PLGA-PEG-TAT 
NH2-PEG-COOH with Mw of 10,000 Da was used to fabricate PLGA-PEG-TAT 
copolymer. PLGA was firstly conjugated to NH2-PEG-COOH by the reaction between 
the carboxylic group of PLGA and the amine group of NH2-PEG-COOH which is similar 
with PLGA-PEG conjugation described in the previous session. Subsequently, the 
protected-TAT peptide with the sequence of NH2-YGRKKRRQRRR was conjugated to 
PLGA-PEG through the carboxylic group on its PEG [138, 139]. Briefly, DCC, NHS 
dissolved in DCM was added to the solution of PLGA-PEG-COOH in DCM to activate 
the carboxylic group of PLGA-PEG-COOH under room temperature for 6 h. Upon 
completion, the activated polymer was then precipitated with ice-cold diethyl ether, and 
centrifuged to recover the activated polymer. The product was further vacuum-dried 
overnight. The coupling reaction of protected-TAT and activated PLGA-PEG-COOH to 
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form PLGA-PEG-TAT was carried out for 24 h in DCM. The product was purified by 
being precipitated in ice-cold diethyl ether and dried. The conjugated TAT was 
deprotected by mixing the TAT-conjugated copolymer to the cocktail containing 95% 
TFA, 2.5% TIS, and 5% DI water for 3 h. PLGA-PEG-TAT was precipitated in ice-cold 
diethyl ether and centrifuged to recover the polymer as pellet. The polymer was vacuum-
dried and further purified by dialyzing against DI water (MWCO: 3,000 Da) for 1 day. 
The final product was freeze-dried for subsequent use. 
 
3.2.5 Characterization of polymers 
The amount of free amine group in the unconjugated PEG (PEG-amine or PEG-diamine) 
after coupling reactions was quantified by Ninhyidrin assay. Ninhydrin is a chemical that 
reacts with free amines of PEG to produce purple color salt. The amount of the resultant 
purple color salt can be detected with a UV-vis spectrophotometry at 570 nm. 
 
1H NMR spectrum of the samples was recorded on a Bruker AMX 500 spectrometer 
using deuterated chloroform (CDCl3) and deuterated dimethyl sulfoxide (DMSO-d6) as 
solvents at 25°C.  
 
Molecular weight of the copolymers was measured using an Aligent high performance 
liquid chromatography - gel permeation chromatography (HPLC-GPC) system equipped 
with a differential refractive index (RI) detector and PLgel 5 µm mixed-D column (7.5 x 
300 mm). THF was used as eluent at a flow rate of 1 mL/min at 25ºC. The injection 
volume was 20 µl. A series of narrow polystyrene standards were used for calibration. 
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3.2.6 Critical micelle concentration (CMC) 
Fluorescence spectroscopy was used to estimate the critical micelle concentration (CMC) 
of PLGA-PEG, PLGA-PEG-FOL, PLGA-PEG-TAT copolymers in PBS using pyrene as 
a hydrophobic fluorescent probe [261]. Briefly, a series of solutions containing 0.0025 – 
25 mg/L copolymers and 0.6 µM pyrene were prepared and allowed to equilibrate at 
room temperature overnight under gentle shaking. The excitation spectra were recorded 
from 300 to 360 nm with an emission wavelength at 390 nm [262]. The intensity ratios of 
I337.5/I334.5 were plotted against the logarithm of polymer concentration. The CMC value 
was estimated as the point of the intersection of the best fit lines at low and high 
concentration respectively. 
 
3.2.7 Preparation and characterization of doxorubicin loaded polymeric micelles 
DOX-loaded micelles with different weight percentage of 3 polymers (i.e., PLGA-PEG, 
PLGA-PEG-FOL and PLGA-PEG-TAT) were prepared  using dialysis method as 
previously described with slight modification [257]. First, DOX.HCl was neutralized 
with twice the number of mole of TEA in DMSO overnight to obtain the DOX free base 
in hydrophobic form [263]. The mixtures of polymers were dissolved in DMSO at a total 
concentration of 10mg/ml. The DOX solution was added into the polymer solution and 
mixed by vortex for 10min. The mixture was transferred into dialysis bag (MWCO: 3,000 
Da) for dialyzing against DI water for 2 days to produce micelles and remove untrapped 
DOX and TEA. The resultant micelles are represented as the weight percentage of the 
polymer contained the functional moiety used in preparing the micelles. For example, 
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TAT(10)/FOL(20)-modified micelles implies the micelles were prepared from 10 wt% 
PLGA-PEG-TAT:20 wt% PLGA-PEG-FOL:70 wt% PLGA-PEG. 
 
The hydrodynamic size and zeta potential of polymeric micelles were measured at 25°C 
by Nano Sizer (Malvern Instruments, UK). Aqueous micelle solutions were prepared 
using deionized water. The concentration of polymeric micelles was kept at 1 mg/ml. The 
micelle solutions were filtered through a 0.80 µm cellulose membrane filter before 
measurements. The average values were calculated from at least 3 measurements 
performed on each samples. To determine DOX loading level and encapsulation 
efficiency, 1 mg of DOX-loaded micelles was dissolved in 1 ml DMSO. The DOX 
concentration was estimated with UV-vis spectrophotometry at 480 nm. The DOX 
content was determined using the calibration curve of DOX in DMSO range from 0 to 50 
µg/ml. 
 
3.2.8 In vitro release of doxorubicin (DOX) 
DOX-loaded micelle solutions (2 mg in 1 ml of PBS, pH 7.4) were transferred to dialysis 
tube (MWCO: 2,000 Da) and dialyzed against 3 ml PBS in a tube at 37°C with shaking at 
100 rev/min. To measure the release of DOX at different time intervals, PBS solution in 
the tube was all withdrawn and replaced with 3 ml fresh PBS. The content of DOX in 
PBS was determined using microplate reader (Tecan – Infinite M200, Austria). Briefly, 
PBS solution was transferred to 96-well plate and detected by microplate reader with 
excitation wavelength at 480 nm and emission wavelength at 570 nm. The release amount 
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of DOX was determined using the calibration curve of DOX in PBS range from 0 to 10 
ppm. The drug release studies were performed in triplicate for each of the samples. 
 
3.2.9 Preparation of Coumarin 6-loaded micelles 
Coumarin 6 (C6)-loaded micelles were prepared by a similar dialysis method used for 
DOX- loaded micelles. Briefly, 1.5 mg of C6 and 30 mg of polymers were dissolved in 3 
ml of DMSO. This solution was then transferred into the dialysis bag (MWCO: 3,000 Da) 
for dialyzing against DI water for 2 days to produce micelles and removed untrapped C6. 
The micelles were lyophilized to solid powder form. 
 
3.2.10 In vitro cellular uptake 
The cell target and cell penetration tests of micelles with and without TAT/FOL were 
carried out in KB cells by labeling the micelles with C6.  The cells were cultured in 12 
mm round glass coverslips placed in 24-well plates for 1 day. Cells were then treated 
with 30 µM C6-loaded micelles for 3 h. Since TAT peptide was reported to penetrate cell 
membrane within 4 min [264], the chosen incubation times were sufficient to 
demonstrate the TAT activity. Subsequently, cells were washed 3 times with cold PBS, 
fixed with 4% cold paraformaldehyde for 30 min at room temperature, and washed with 
PBS again. The fixed cells on were observed under confocal microscope (Nikon C1, 
Japan) at excitation wavelength of 480 nm and emission wavelength of 590 nm. 
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3.2.11 In vitro cytotoxicity of DOX-loaded micelles 
The ability of DOX-loaded micelles to inhibit cell proliferation was evaluated using 
human KB carcinoma cell line with MTT viability assay. Cells cultured in free folic 
RPMI media supplemented with 10% FBS and 1% penicillin-streptomycin at 37°C in 
humidified environment of 5% CO2 were seeded onto 96-well plates at a seeding density 
of 5000 cells/well and incubated for 48 h to permit cell attachment. The cells were then 
treated with DOX-loaded micelles at different concentrations for 3 days. After 3 days of 
incubation, the cells were washed once with PBS, and grown for another 48 h. The 
growth medium was then replaced with free serum medium containing 0.5 mg/mL MTT 
and incubated for 4 h. MTT containing medium was next discarded and replaced with 
150 µl DMSO to dissolve the formazan crystals for 15 min under shaking. The samples 
were then analyzed with a microplate reader (Tecan – Infinite M200, Austria) using a test 
wavelength of 570 nm and a reference wavelength of 630 nm. The data were presented as 
mean and standard deviation of 6 replicates.  
 
3.3 Results and discussion  
3.3.1 Characterization of PLGA-PEG 
PLGA-PEG was synthesized by the reaction between carboxylic group of PLGA (Mw: 
5,600 Da) and primary amine group of PEG (Mw: 5000 Da). Therefore, the coupling 
reaction could be confirmed by the disappearance of the primary amine group of PEG-
amine reactant in the resultant product. Ninhydrin assay which is able to detect the 
presence of amine group was carried out to determine the   amount of unconjugated PEG 
in the final PLGA-PEG product [265]. Ninhydrin results suggest that the coupling 
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reaction occurred and PLGA-PEG was produced with the presence of 15.6 ± 1.7 % of 
unconjugated PEG in the product.  
 
Figure 3.2 1H NMR spectra of (A) PLGA-PEG, (B) PLGA-PEG-FOL, and (CDDP) 
PLGA-PEG-TAT. 
 
In addition, 1H NMR analysis shows that PLGA-PEG was successfully synthesized. From 
Figure 3.2A, the multiple peaks at δ3.5-3.7 are from the proton of CH2 groups in PEG. 
 56 
The lactic proton and glycolic protons of PLGA are indicated by the presence of the 
peaks at δ5.2 and δ4.8, respectively [266]. The molecular weight of the final product 
PLGA-PEG was characterized by GPC. The GPC results further indicate that PLGA-PEG 
polymer was successfully prepared.  
 
3.3.2 Characterization of PLGA-PEG-FOL 
PLGA-PEG-FOL polymer was characterized using GPC, 1H NMR, ninhydrin and UV 
spectroscopy. Similar to PLGA-PEG synthesis, ninhydrin tests indicate that the purity of 
PLGA-PEG-FOL is approximately 84.9± 0.6 %. Figure 3.2B shows the peaks at δ3.5-3.7, 
δ5.2 and δ4.8 which are assigned to PEG and PLGA as mentioned in the previous 
session. In addition, the presence of the new peaks at δ6.6 and δ7.6, which belong to the 
protons on the benzene ring of FOL, indicates that PLGA-PEG-FOL was successfully 
synthesized [257]. Compared to Figure 3.2A, the PEG peak in the Figure 3.2B is more 
intensive because larger PEG polymer (Mw: 10,000 Da) was used for PLGA-PEG-FOL 
fabrication. GPC result further verifies that PLGA-PEG-FOL was prepared with a low 
amount of impurity. Furthermore, UV spectroscopy measuring the amount of FOL also 
confirms 82.7± 1.0 % purity of PLGA-PEG-FOL product.  
 
3.3.3 Characterization of PLGA-PEG-TAT 
In this study, the short sequence of TAT peptide was used since it was previously showed 
to increase cellular internalization of carriers more efficiently as compared to longer TAT 
sequences [267]. Figure 3.2C shows the 1H NMR spectrum of PLGA-PEG-TAT. The 
new peaks at δ6.6 and at δ7.0 present to the protons from the benzene ring in tyrosine of 
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TAT peptide [138]. By comparison the intensity of the peaks attributed to PLGA and 
TAT, the yield of TAT coupling is estimated at around 40%.  
 
3.3.4 Critical micelle concentration (CMC)  
The copolymers consisting of hydrophobic and hydrophilic blocks can self-assemble to 
form micelles in aqueous solution. The formation of micelles with PLGA-PEG, PLGA-
PEG-FOL and PLGA-PEG-TAT was evidenced by the existence of CMC measured 
using fluorescence spectroscopy with pyrene as the fluorescence probe. As shown in 
Figure 3.3, the gradual shift of the peak in the excitation spectra of pyrene from 334.5 to 
337.5 is observed, indicating the change in the vibration structure of the pyrene emission. 
At low polymer concentration, the intensity ratio of I337.5/I334.5 does not change much. 
However, at high polymer concentration (above CMC value), the intensity ratio changes 
sharply, which indicates the presence of pyrene in the hydrophobic core of micelles. The 
CMC of non-modified micelles (100% PLGA-PEG), FOL(10)-micelles (10 wt% PLGA-
PEG-FOL:90 wt% PLGA-PEG), TAT(10)-micelles (10 wt% PLGA-PEG-TAT:90 wt% 
PLGA-PEG), and TAT(10)/FOL(10)-micelles (10 wt% PLGA-PEG-TAT:10 wt% 
PLGA-PEG-FOL:80 wt% PLGA-PEG) micelles are 3.61 mg/L, 3.68 mg/L, 4.34 mg/L 
and 5.50 mg/L respectively. 
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Figure 3.3 Plot of I337.5/I334.5 ratio as a function of polymer concentration (Log C) in PBS. 
(A) PLGA-PEG, (B) 10 PLGA-PEG-FOL: 90 PLGA-PEG, (CDDP) 10 PLGA-PEG-
TAT: 90 PLGA-PEG, and (DOX) 10 PLGA-PEG-TAT: 10 PLGA-PEG-FOL: 80 PLGA-
PEG. 
 
Among all the micelles, the CMC of micelles with FOL and TAT functional groups are 
slightly higher than that of the non-modified micelles. A possible reason is that the 
molecular weight of PEG used in PLGA-PEG-FOL and PLGA-PEG-TAT is larger than 
that used in PLGA-PEG which reduces the hydrophobicity of the polymers. As a result, 
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larger amount of polymers are needed to form the micelles. Moreover, TAT(10)-micelles 
have higher CMC values than FOL(10)-micelles. This is because of the strong interaction 
of TAT with water molecules [138] hence even more PLGA molecules are needed to 
form the core of TAT-modified micelles. As mentioned above, the composition of 
TAT(10)/FOL(10)-micelles contains both PLGA-PEG-FOL and PLGA-PEG-TAT with 
10 wt% of each polymer; therefore, their CMC is higher than FOL(10)-micelles and 
TAT(10)-micelles. 
 
3.3.5 Particle size, zeta potential  












Non-modified micelles 1.91 47.8 63.74 0.184 -13.30 
FOL(10)-micelles 2.03 50.8 94.61 0.219 -12.25 
TAT(10)-micelles 2.10 52.5 81.07 0.235 -13.00 
TAT(10)/FOL(10)-micelles 1.95 48.8 106.30 0.251 -9.48 
 
The size of drug delivery carriers is important since it influences drug efficacy and 
pharmacokinetics. Hobbs et al. [268] showed that liposomes with diameters from 100 nm 
– 200 nm were more efficient in diffusing along the vessel of tumors than larger 
liposomes. Moreover, it was proven that the uptake of the reticuloendothelial system 
(RES) is size dependent, the smaller size of carriers would result in the lesser uptake; 
therefore, the clearance would be reduced [269]. The size of all micelles in this study is 
less than 200 nm, which indicates the suitability for drug delivery (Table 3.1). Compared 
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to previously TAT-micelle system based on TAT-PEG-cholesterol with the size at around 
200 nm, our reported TAT/FOL-modified micelles with smaller size are more suitable for 
drug delivery by reducing the RES uptake. In addition, the zeta potential of particles also 
plays an important role in RES uptake. It was proven that the RES uptake of particles 
cannot be avoided if their zeta potential values are above -5 mV [269]. The zeta potential 
values of the micelles used in this study are lower than -5 mV (Table 3.1), which indicate 
that the micelles can escape from the RES uptake. 
 
3.3.6 In vitro drug release and drug loading 
Drug loading content (DLC) and encapsulation efficiency (EE) in different micelle 
formulations (Table 3.1) shows no significant difference in the amount of DOX-loaded 
among non-modified micelles, FOL(10)-micelles, TAT(10)-micelles and 
TAT(10)/FOL(10)-micelles. DOX was successfully incorporated into the core of micelles 
by physical interaction with drug loading content of approximately 2%. Similarly, the 
DOX release profiles from all four micelles shown in Figure 3.4 are almost the same with 
less than 10%, 15% release within the first 6 h and 24 h respectively. Then the drug is 
slowly released and maintains more than 60% of the drug in the micelles after 12 days 




Figure 3.4 In vitro release profiles of DOX from different kinds of micelles. The 
experiments were conducted in triplicate in PBS (pH 7.4) at 37ºC. The standard deviation 
of these drug release curves is not shown to make the figure to be seen easily. The 
standard deviation is quite small (less than 10%). 
 
Compared to previously reported DOX- loaded polymeric micelle systems prepared from 
other amphiphilic materials, such as poly(N-isopropylacrylamide-co-N,N-
dimethylacrylamide-co-2-aminoethyl methacrylate)-poly(10-undecenoic acid) (2.5% 
DLC and 40% drug release within the first 24 h [270]), the PLGA-PEG system used here 
exhibits a more sustainable DOX release rate and reasonable DLC. 
 
3.3.7 Cytotoxicity of DOX- loaded micelles 
As proven in previous studies, functional moieties should be located above the carrier 
surface for the unhindered interaction between the moieties with the cells [137]. 
Therefore, a higher molecular weight of PEG was used for fabrication of PLGA-PEG-
FOL and PLGA-PEG-TAT polymers compared to PLGA-PEG. To quantitatively 




























model. To assess the changes in proliferation, the cells were incubated with DOX- loaded 
micelles for 72 h and examined using the MTT assay. The toxicity of all blank micelles 
without loaded drug to KB cells was measured at a tested concentration of 2.0 mg/mL for 
72 h. The polymer concentration used in the blank micelle tests was higher than the 
concentration of polymers in all cytotoxicity tests with the presence of DOX. Blank 
micelle tests indicate that micelles at concentration of 2.0 mg/mL were practically non-
toxic to KB cells. 
 
3.3.7.1 Effect of PLGA-PEG-FOL concentration on FOL-modified micelles 
The targeting ability of FOL-modified micelles relies on the specific binding between 
FOL and FOL receptors. Hence the amount of FOL on the surface of micelles can affect 
the targeting ability of micelles. It was reported that few FOL molecules on the micellar 
surface reduced the binding ability, however, too many FOL molecules on the surface 
also decreased targeting ability and affect normal cells [257]. Therefore, the cytotoxicity 
effect of DOX-loaded FOL-micelles with various FOL concentrations has been 
investigated. Four micelle systems with 0-30 wt% PLGA-PEG-FOL in the polymer 
carriers are selected for the demonstration and named as non-modified micelles, 
FOL(10)-micelles, FOL(20)-micelles and FOL(30)-micelles. The number in the bracket 
indicates the weight percentage of PLGA-PEG-FOL in the blend of PLGA-PEG and 
PLGA-PEG-FOL used in preparing micelles. 
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Figure 3.5 Effect of FOL concentration of the FOL-micelles on the viability of KB cells 
after being treated with 4 types of DOX- loaded micelles: non-modified micelles, 
FOL(10)-micelles, FOL(20)-micelles, and FOL(30)-micelles for 3 days. 
 
The cell viability of KB cells after being treated under different DOX concentration using 
FOL(0-30)-micelles is shown in Figure 3.5. The cell viability first decreases when 
increasing FOL concentration up to 20% because the interaction between micelles and 
cells is stronger with higher popular of FOL on the micelle surface. On the other hand, 
micelles with higher density of FOL ligand on a surface interact with larger amount of 
FOL receptors on the cell membrane that may also leads to lower micelles internalization 
rate. Increasing FOL concentration in each micelle leads to the faster delivery of FOL 
into cancer cells. Hence, FOL receptor recycling system is down-regulated faster because 
of the faster satisfaction of the FOL requirement of cancer cells. Therefore, further 
increase of FOL content to 30% cannot help to increase the efficiency of the micelles in 





















the lowest IC50 (0.273 µM) is from FOL(20)-micelles. However, this optimal FOL 
concentration (20%) is lower than our previous PLGA-PEG-FOL studies (40-65%) [257]. 
In our previous study, the PEG with the same molecular weight was used for the 
synthesis of both PLGA-PEG and PLGA-PEG-FOL. Therefore, more amount of FOL in 
the micelles could be needed in order to get the maximum targeting compared to this 
study in which higher molecular weight of PEG was used in PLGA-PEG-FOL synthesis. 
  
Table 3.2 IC50 values of DOX incorporated micelles with various surface modifications 





Non-modified micelles* 0.529 
FOL(10)-micelles*  0.326 
FOL(20)-micelles  0.273 




*DOX-loaded micelle systems with different surface modifications (See Section 3.3.7.3). 
 
3.3.7.2 Effect of FOL concentration on TAT/FOL-modified micelles 
TAT peptide is a non-selective peptide thus it is able to penetrate into both cancer and 
normal cells. Besides, its high positive charge may change the surface charge of the 
system to a more positive charged one which increases the RES uptake. Hence, low 
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amount of TAT should be used in order to obtain micelles with minimal non-selective 
penetration and RES uptake. It was proven that micelle systems with 2 mol% TAT were 
good for the homo distribution of micelles and less precipitated than the micelles with 
higher than 2 mol% TAT by more than 2 times [173]. Although some recent studies used 
100% TAT-conjugated polymers to form carriers [138, 139, 173], 10 wt% PLGA-PEG-
TAT polymer was used in this project to obtain micelles with approximately 2.5 mol% 
TAT. The advantages of using such a low amount of TAT are to reduce the RES uptake 
by maintaining a negative charged system and minimizing non-selective penetration. 
 
The previous section shows that the most efficient FOL-micellar system is FOL(20)-
micelles. However, the addition of TAT moiety may change the optimal concentration of 
FOL in the micelles. Therefore, DOX- loaded TAT/FOL micelles with the blending of 10 
wt% PLGA-PEG-TAT and 0-20 wt% of PLGA-PEG-FOL, or TAT(10)/FOL(0-20)-
micelles, were investigated. From Table 3.2, the IC50 values of DOX- loaded TAT/FOL 
micelles decrease as the amount of FOL on the surface increases (0.293 µM, 0.171 µM 
and 0.147 µM for TAT(10)-micelles, TAT(10)/FOL(10)-micelles and TAT(10)/FOL(20)-
micelles respectively. While a significant decrease in the IC50 of TAT(10)/FOL(10)-
micelles compared to TAT(10)-micelles is observed, only a decrease is shown when 
increasing the FOL from 10% to 20%. Moreover, the anticancer efficacy of 
TAT(10)/FOL(20)-micelles is similar or even lower than TAT(10)/FOL(10)-micelles at 
high treatment concentrations (Figure 3.6). This phenomenon is similar with the FOL 
effect as described in the previous section (3.3.7.1). It may due to the high density of 
FOL molecules on the micellar surface that interfere the activity of TAT molecules to the 
 66 
cancer cells. Therefore, TAT(10)/FOL(10)-micelles would be sufficient to enhance 
cancer treatment against KB cells, with low IC50 of 0,171 µM, which is nearly two times 
lower than the micelles with single functional moiety. 
 
 
Figure 3.6 Effect of FOL concentration of the TAT(10)/FOL-micelles on the viability of 
KB cells after being treated for 3 days using 3 types of DOX-loaded micelles: TAT(10)-
micelles, TAT(10)/FOL(10)-micelles, and TAT(10)/FOL(20)-micelles. 
 
3.3.7.3 Effect of different functional moieties on the cancer treatment efficacy of micelles 
Combining the data set in Section 3.3.7.1 and this section allows us to compare the effect 
of TAT and FOL functional moieties on the anticancer efficacy of DOX-loaded micelles. 
Table 3.2 shows that the IC50 of non-modified micelles are approximately 1.6, 1.8 and 3 
times higher than FOL(10)-micelles, TAT(10)-micelles and TAT(10)/FOL(10)-micelles 
respectively. This suggests that multi-functional micelle system is a better system since it 




















This TAT(10)/FOL(10) system shows higher efficiency than the previous system [137] 
using TAT- micelles based on TAT- PEG-phosphatidylethanolamine, which only showed 
less than 2 times enhancement compared to the non-modified micelles. As reported for a 
TAT- pH sensitive micelle system, the TAT- micelles showed from around 0.3 to less 
than 1.8 times enhancement at pH conditions ranging 6-7 compared to the non-modified 
micelles [271]. The results indicate that this multi-functionalized micelle system, 
TAT(10)/FOL(10)-micelles, is potentially useful for drug delivery applications. 
 
3.3.8 Cellular uptake  
Figure 3.7 shows the confocal images of KB cells incubated with C6-loaded micelles. As 
can be seen, TAT/FOL-modified micelles entered the cells more efficiently than micelles 
without or with only FOL or TAT. The stronger fluorescence intensity in Figure 3.7B and 
3.7C compared to that of Figure 3.7A indicates that 10% PLGA-PEG-FOL or 10% 
PLGA-PEG-TAT in the micelle formulation could enhance the cellular uptake ability of 
micelles. Together with the FOL targeting group, the TAT/FOL-modified micelles 
exhibit enhanced cellular uptake of the drug (Figure 3.7D). The result indicates that the 




Figure 3.7 Confocal images of KB cells treated with fluorescence (C6) labeled (A) non-




In this study, PLGA-PEG, PLGA-PEG-FOL and PLGA-PEG-TAT copolymers were 
successfully synthesized. Four micelles with different ratio of PLGA-PEG, PLGA-PEG-
FOL and PLGA-PEG-TAT copolymers were fabricated with low CMC. All micelles had 
small size for drug delivery. Micelles with both TAT and FOL modification were able to 
enter KB cells more efficiently. Due to enhancement in cellular uptake, TAT/FOL-
modified micelles achieved higher cytotoxicity compared to non-modified micelles, 
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FOL-modified micelles, or TAT-modified micelles. Such TAT/FOL modified micelles 
represent a promising drug carrier system for drug delivery. To further develop the multi-
functionalized micellar drug delivery system invested in this chapter, the following two 
chapters (Chapter 4 and 5) describes the methods for investigation of synergistic 
combination delivery using TAT/FOL-functionalized micelles. By controlling the ratio of 
released drugs at synergistic regime, synergistic treatment efficacy can be obtained. 
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CHAPTER 4. Synergistic co-delivery of doxorubicin and 
paclitaxel using multi-functionalized micelles for cancer 
treatment 
 
4.1 Introduction  
Single agent therapy has seen limited success in cancer treatment due to the toxicity at 
high drug dosage, the heterogeneity of cancer cells and the drug resistance [212-215]. 
Therefore, combination therapy has been preferred in different cancer treatment due to its 
lower toxicity at the required effect. In addition, synergistic combinations could promote 
the response rate compared to single drugs and result in the higher therapeutic effect.  
 
With different activities to cancer cells, the pairing of chemotherapeutic agents (DOX 
and PTX) for combination treatment can have higher and synergistic therapeutic effect. 
DOX works by binding to DNA and inhibiting nucleic acid synthesis while PTX 
promotes microtubule assembly from tubulin dimers and stabilizes microtubules by 
preventing depolymerization [12]. Due to the different mechanism of DOX and PTX on 
cancer cells, several studies have been conducted to study the value of the combination of 
DOX and PTX in cancer treatment. Firstly, this drug combination has shown enhanced 
response rate and patient survival rate in breast cancer treatment [213]. In addition, these 






Figure 4.1 Strategies to delivery of DOX and PTX at synergistic ratio to the cancer cells via micellar systems: (A) DOX and PTX 
encapsulated separately into FOL modified micelles (DOX-FOL micelles & PTX-FOL micelles) were co-delivered into cancer cells; 
(B) co-delivery of DOX- TAT/FOL micelles & PTX-TAT/FOL micelles with the utilization of TAT to enhance the treatment efficacy; 
(CP) and (D) dual drugs, DOX and PTX, were simultaneously encapsulated into the FOL modified micelles or TAT/FOL micelles to 
form DOX/PTX-FOL micelles and DOX/PTX-TAT/FOL micelles respectively.  
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In this chapter, a novel drug delivery system based on polymeric micelles with 
multifunctional surface properties has been developed for the combination of two 
anticancer drugs DOX and PTX. The effects of different free drug combinations on the 
mouth epidermal carcinoma KB cells was first investigated, and the combination that 
exhibits good synergy over a wide treatment concentration range has been chosen as the 
guide composition for subsequent drug-encapsulating studies. Secondly, co-delivery of 
two single drug-loaded micelles using FOL modified system (DOX-FOL micelles & 
PTX-FOL micelles) in Figure 4.1A and TAT/FOL modified system (DOX-TAT/FOL 
micelles & PTX-TAT/FOL micelles) in Figure 4.1B were then investigated. Finally, dual 
drugs-encapsulated micelles with FOL modification (Figure 4.1C) and TAT/FOL 
modification (Figure 4.1D) were evaluated. 
 
4.2 Experimental section 
4.2.1 Materials 
Three self-synthesized block copolymers (PLGA-PEG, PLGA-PEG-FOL and PLGA-
PEG-TAT) in Chapter 3 were used in this study as carrier materials. Dimethyl sulfoxide 
(DMSO) and triethylamine (TEA), 3-[4,5-dimethylthiazolyl-2]-2,5-diphenyl tetrazolium 
bromide (MTT), tween 80 and paclitaxel (PTX) were all purchased from Sigma-Aldrich 
(USA). Doxorubicin (DOX) was obtained from Boryung (Korea). Methanol, acetonitrile 
(ACN), tetrahydrofuran (THF), chloroform, diethyl ether were purchased from Tedia 
(USA). Folate-free RPMI 1640 medium, fetal bovine serum (FBS), Trypsin-EDTA and 
penicillin-streptomycin were obtained from Invitrogen (USA). Human oral cavity 
carcinoma KB cell line was purchased from ATCC (USA). Reagent graded de-ionized 
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(DI) water was obtained from the Milli-Q Plus System (Millipore, USA). All chemicals 
were used directly without further purification. 
 
4.2.2 Preparation and characterization of doxorubicin (DOX) and paclitaxel (PTX) 
loaded polymeric micelles 
4.2.2.1 Preparation of micelles 
D-loaded micelles were prepared using dialysis method as previously described with 
slight modification [257]. First, DOX.HCl was neutralized with twice the number of mole 
of TEA in DMSO overnight to obtain the DOX free base (hydrophobic form) [263]. The 
mixtures of PLGA-PEG, PLGA-PEG-FOL, PLGA-PEG-TAT at various weight ratios 
were dissolved in DMSO at a total concentration of 10 mg/ml. The DOX solution was 
added into the polymer solution and mixed by vortex for 10 min. The mixture was 
transferred into dialysis bag (MWCO: 3,000 Da) for dialyzing against DI water for 2 days 
to produce micelles and remove untrapped DOX and TEA.  
 
PTX-loaded micelles were prepared by three steps: (1) dissolving of PTX and mixture of 
three polymers as mentioned above into DCM, (2) evaporating DCM to form a thin film 
matrix and (3) forming micelles by adding water into the film under stirring. Further 
purification by dialyzing against DI water was carried to remove un-encapsulated drug. 
 
Combination DOX/PTX-loaded micelles were produced using the thin film evaporation 
method as described in the above paragraph for PTX-loaded micelle preparation. 
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However, DOX.HCl was first neutralized with TEA in a very low amount of DMSO 
before being adding into the DCM solution of PTX and polymers.   
 
4.2.2.2 Characterization of DOX-  and PTX-loaded polymeric micelles 
The hydrodynamic size and zeta potential of polymeric micelles were measured at 25°C 
by NanoSizer (Malvern Instruments, UK). Aqueous micelle solutions were prepared 
using deionized water. The concentration of polymeric micelles was kept at 1 mg/ml. The 
micelle solutions were filtered through a 0.80 µm cellulose membrane filter before 
measurements. The average values were calculated from at least 3 measurements 
performed on each samples.  
 
The drug loading content (DLC) and encapsulation efficiency (EE) of DOX in micelles 
was estimated with a UV-vis spectrophotometry at 480 nm by dissolving 1 mg of DOX-
loaded micelles in 1 ml DMSO. The DOX content was determined using the calibration 
curve of DOX in DMSO range 0 - 50 µg/ml.  
 
The amount of PTX in micelles was analyzed using a high performance liquid 
chromatography (HPLC, Agilent 1200, USA) equipped with a ZORBAX 300SB-C18 
column. The micelles were dissolved in DCM to destroy the micellar structure and 
dissociate PTX from the polymers. The samples were then flowed through the column 
with a solution of ACN/water (50/50, v/v) as a mobile phase. The PTX was detected with 
a UV detector at 265 nm wavelength. A calibration of PTX was established at low 
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concentration from 0.5 to 50 µM/mL for the quantitative calculation of PTX 
concentration.   
 
4.2.3 In vitro release study 
DOX-loaded micelle solutions (2 mg in 1 ml of PBS, pH 7.4) were transferred to dialysis 
tube (MWCO: 2,000 Da) and dialyzed against 3 ml PBS in a tube at 37°C with shaking at 
100 rev/min. To measure the release of DOX at different time intervals, PBS solution in 
the tube was all withdrawn and replaced with 3 ml fresh PBS. The withdrawn solutions 
were transferred to 96-well plate and analyzed by a microplate reader (Tecan – Infinite 
M200, Austria) with excitation wavelength at 480 nm and emission wavelength at 570 
nm to determine the amount of DOX in that solutions. The absolute amount of DOX was 
determined using the calibration curve of DOX in PBS range from 0 to 10 ppm. The drug 
release studies were performed in triplicate for each of the samples. 
 
The method for investigation of PTX release was similar with the above method used for 
DOX-loaded micelles. However, the addition of 0.05 w/v% of Tween 80 into the PBS 
solution was applied in this study due to the less solubility of PTX in the pure PBS. The 
released PTX in the PBS solutions was extracted into the organic phase for HPLC 
analysis by adding equal volume of DCM into the PBS solutions. The solutions were 
further mixed for 24 h before discarding the PBS for the completion of PTX extraction 
into DCM. The amount of PTX was determined using the method as used for the 
determination of the loading amount of PTX in micelles. 
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4.2.4 In vitro cytotoxicity study 
The ability of various treatments to inhibit cell proliferation was evaluated using human 
carcinoma KB cell line with MTT viability assay. Cells cultured in free folic RPMI 
media supplemented with 10% FBS and 1% penicillin-streptomycin at 37°C in 
humidified environment of 5% CO2 were seeded onto 96-well plates at a seeding density 
of 10,000 cells/well and incubated for 2 days to permit cell attachment. The cells were 
then treated with free drugs or micelles at different concentrations for 2 days. Afterwards, 
the cell viability was analyzed by MTT assay as described clearly in Chapter 3. 
 
4.2.6 Determination of combination effects  
Effects of the DOX and PTX combination were analyzed by a Calcusyn software 
(Biosoft, USA) derived from the Chou and Talalay’s principle [232, 233] as described in 
Chapter 2.  CI values of free drug combinations (DOX/PTX) were determined using 
equation 2-2, with (Dosex)1 and (Dosex)2 being the concentration of free DOX and free 
PTX in single treatments that kill x % KB cells, (Dose)1 and (Dose)2 being the 
concentration of free DOX and free PTX in the combination. CI values of DOX/PTX 
combinations in micellar forms were determined with (Dosex)1 and (Dosex)2 being the 
DOX-loaded micelles and PTX-loaded micelles in single micellar treatments that kill x % 




4.3 Results and discussion  
4.3.1 In vitro cytotoxicity interaction between free doxorubicin (DOX) and free 
paclitaxel (PTX)  
This study has been designed to investigate the synergistic drug combination based on 
DOX and PTX for cancer treatment using KB cell line for all experiments. The changes 
in the cytotoxicity effect of combined DOX/PTX were investigated at different ratios to 
find out the synergistic DOX/PTX ratio for KB cell treatment. The combinations of free 
DOX and free PTX are presented as DOX/PTX_x/y while x/y is the molar ratio of 
DOX/PTX in the combination.  
 
Table 4.1 IC50 of different treatment compositions of free drugs, DOX and P, to KB cells 
after 2 days incubation.  
Treatment compositions IC50 (µM) 
DOX  1.564 
DOX/PTX_1/0.1  0.866/0.0866 
DOX/PTX_1/0.2  0.185/0.037 
DOX/PTX_1/1  0.135/0.135 
DOX/PTX_0.2/1  0.0893/0.447 
DOX/PTX_0.1/1  0.057/0.570  
PTX 0.459  
 
Figure 4.2 shows the response of KB cells treated with different combinations at various 
concentrations. Figure 4.2A shows the KB cell viability after being treated with 
DOX/PTX combinations as the function of DOX concentration. Lower cell viability is 
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observed when a higher ratio of DOX/PTX is used for all DOX-based combinations 
(DOX/PTX_1/0.1, 1/0.2, 1/1). Moreover, the IC50 values of DOX in DOX-based 
combinations are 2-10 times lower than that of free DOX treatment (Table 4.1). 
However, minimal change in cell viability (Figure 4.2B) and IC50 values of PTX (Table 
4.1) are observed when a low amount of DOX is added into the PTX-based combinations 




Figure 4.2 Cytotoxicity of DOX and PTX combinations at (A) higher ratio of DOX and 
(B) higher ratio of PTX against KB cells for 2 days treatment. 
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These results suggest that (1) the DOX-based combinations is better than PTX-based 
combinations, (2) the DOX-based combinations may exhibit a synergistic effect and (3) 
PTX-based combinations with low amount of DOX may not exhibit any synergistic effect 
for the KB cell treatment. However, the good synergistic combination may not be able to 
determine from the data as shown in Figure 4.2 or Table 4.1. Therefore, further analysis 
needs to be carried on these cytotoxicity results to obtain the more quantitative data using 
Calcusyn software. 
 
Figure 4.3 Plot of the combination index (CI) as the function of cell viability for KB 
cells treated with free DOX and free PTX combinations. 
 
The effect of DOX/PTX combinations can be presented more clearly by CI values in 
Figure 4.3 with cell viability as the dependent value. The CI values of all combinations at 
fixed ratios of DOX/PTX of 1/0.1, 1/0.2, 1/1, 0.2/1 and 0.1/1 as a function of the cell 
viability from 5% to 98% was simulated and presented in Figure 4.3 as the similar 
method shown in previous studies [219, 272]. A decrease in PTX in the DOX-based 
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combinations from DOX/PTX_1/1 to DOX/PTX_1/0.2 could reduce the CI values of the 
combination. However, further reducing PTX, to the ratio of DOX/PTX_1/0.1, does not 
further reduce the CI value. For the PTX-based combinations, the CI values increase with 
the decrease in the amount of added DOX as compared the CI values among 
DOX/PTX_1/1, DOX/PTX_0.2/1 and DOX/PTX_0.1/1. Higher antagonistic interaction 
(CI > 1) of DOX and PTX is observed in the PTX-based combinations (DOX/PTX_0.2/1 
and DOX/PTX_0.1/1). However, higher synergistic interaction (CI < 1) is observed in the 
DOX-based combinations. The DOX/PTX_1/0.2 combination shows the lowest CI values 
with below 1 for all treatment concentrations that result in 5 - 98% cell viability. 
Therefore, DOX/PTX_1/0.2 combination is chosen as the optimal synergistic 
composition for the following drug-encapsulated studies. 
 
4.3.2 Size and zeta potential characterization of drug-loaded polymeric micelles  
The size of drug delivery carriers is important since it influences drug efficacy and 
pharmacokinetics. Hobbs et al. [273] showed that liposomes with diameters from 100 nm 
– 200 nm are more efficient in diffusing along the vessel of tumors than larger liposomes. 
Moreover, it was proven that the uptake of the reticuloendothelial system (RES) is size 
dependent. Smaller size carriers would have the lesser uptake, and consequently lower 
clearance [274]. All micelles in this study are 130 nm or less in hydrodynamic size (Table 
4.2). The size of TAT/FOL-modified micelles in this study is at 106 nm, which is smaller 
compared to previously TAT-modified micelle system based on TAT-PEG-cholesterol 
with the size at around 200 nm [138]. Hence, our reported TAT/FOL-modified micelles 
are more suitable for drug delivery. In addition, the zeta potential of particles also plays 
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an important role in RES uptake. It was proven that the RES uptake of particles cannot be 
avoided if their zeta potential values are above -5 mV [274]. From Table 4.2, the highest 
zeta potential value among the micelles in this study is less than -9 mV, making them a 
potential multi-targeting candidate to evade RES uptake.  
 
Table 4.2 Characterization of polymeric micelles.  
Micelles DLC   (%) 
EE 
(%) 




DOX-micelles  1.91 
47.8 
63.7 -13.3 
DOX-FOL micelles  2.03 50.8 94.6 -12.3 
DOX-TAT/FOL micelles  1.95 48.8 106.3 -9.5 
PTX- micelles  1.17 54.6 105.2 -15.1 
PTX-FOL micelles  1.20 56.1 113.8 -14.0 
PTX-TAT/FOL micelles  1.12 52.3 132.8 -10.6 





1.44 41.6 (DOX) 
59.1 (PTX) 
123.2 - 9.3 
 
 
4.3.3 In vitro drug release and drug loading of singe drug-loaded micelles 
Drug loading content (DLC) in different single drug-loaded micelle formulations is 
tabulated in Table 4.2 DOX has been successfully incorporated into the core of micelles 
by physical interaction with no significant difference in the amount of loaded DOX 
among the DOX-, DOX-FOL, and DOX-TAT/FOL micelles at the DLC of 




Figure 4.4 In vitro release profiles of (A) DOX from DOX- micelles, DOX- FOL 
micelles and DOX- TAT/FOL micelles; and (B) PTX from PTX-micelles, PTX-FOL 
micelles and PTX-TAT/FOL micelles. The experiments were conducted in triplicate in 
PBS (pH 7.4) at 37ºC. The standard deviation of these drug release curves is not shown to 
make the figure to be seen easily. The standard deviation is less than 15%. 
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Similarly, PTX is also incorporated into the three micelle systems (PTX, PTX-FOL, 
PTX-TAT/FOL) with the same amount of drug content of approximate 1%. The reason of 
lower PTX amount in the micelles compared to DOX is to maintain the small size of 
PTX-loaded micelles. Due to the larger size of PTX molecule and the different in the 
preparation method, PTX-loaded micelles tend to have larger size compared to DOX-
loaded micelles when having the same DLC. The DOX and PTX release profiles from all 
micelles shown in Figure 4.4 are almost the same with less than 10%, 15% release within 
the first 6 h and 24 h respectively. Then the drugs are released slowly released after that. 
The amount of DOX and Pare maintained more than 30% in the micelles after 60 days 
incubation with pH 7.4 PBS.  
 
4.3.4 In vitro drug release and drug loading of dual drug-loaded micelles 
As investigated in the previous section (Section 4.3.1), the combination of DOX and PTX 
exhibits good synergistic effect to KB cells at the molar ratio of DOX/PTX at 
approximately 1/0.2. In addition, it is observed that DOX- loaded micelles and PTX-
loaded micelles have similar drug release rate (Figure 4.4). Therefore, the co-
encapsulated micelles (DOX/PTX-FOL micelles and DOX/PTX-TAT/FOL micelles) 
were prepared from the initial molar ratio of DOX to PTX at 1/0.2.  
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Figure 4.5 In vitro release profiles of DOX/PTX(1/0.25)-loaded micelles conducted in 
triplicate in PBS (pH 7.4) at 37ºC. 
 
The co-encapsulated micelles would ideally have 1 parts of DOX/0.2 part of PTX and 
release the drugs at the DOX/PTX ratio of 1/0.2. However, the DLC and drug release rate 
of DOX and PTX in the co-encapsulated micelles do not result as expected (Table 4.2 
and Figure 4.5). DLC of DOX and PTX in the co-encapsulated micelles is approximately 
1/0.25. This means the encapsulation efficiency of PTX is slightly higher than that of 
DOX.  This may be due to the higher hydrophobicity of PTX compared to D, which 
results in the stronger interaction of PTX to the core of micelles. While the same release 
rates are observed for single drug-loaded micelles, the slower release rate of PTX in the 
DOX/PTX (1/0.25)-loaded micelles is shown in Figure 4.5. It may be due to the much 
lower encapsulation amount of PTX compared to its of DOX in the DOX/PTX (1/0.25)-
loaded micelles. It can be concluded that the PTX amount compared to DOX amount in 
the DOX/PTX-loaded micelles was 20-30% higher than the designed value. However, the 
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release rate of PTX was slower than DOX.  Therefore, the final amount of DOX/PTX 
could be still considered in the designed ratio. 
 
4.3.5 Cytotoxicity enhancement of drug-loaded micelles with the addition of TAT on 
the micelle surface 
DOX or PTX encapsulated micelles with different surface modifications have 
demonstrated enhanced targeting property and cancer treatment effect [259, 275] 
including our previous study with the use of FOL micelles [257]. To further enhance the 
treatment efficiency, the effect of TAT peptide on the performance of drug-loaded 
micelles would be discussed in this study. TAT peptide is a non-selective peptide able to 
penetrate into both cancer and normal cells. Hence, a low amount of TAT should be used 
in order to obtain micelles with minimal non-selective penetration. It has been shown that 
micelle systems with 2 mol% TAT exhibit a homogeneous distribution of micelles and 
less precipitation compared with the micelles with 4 mol% or more TAT [173]. Although 
recent studies used 100% TAT-conjugated polymers to form carriers [138, 139, 173], this 
study aims to demonstrate the possibility of enhancing the treatment efficiency by 
incorporating a very low amount of TAT into drug carriers. Drug-loaded TAT/FOL 
micelles were prepared from 10 wt% PLGA-PEG-TAT polymer to obtain micelles with 
about 2.5 mol% PLGA-PEG-TAT.  
 
The toxicity of all blank micelles was tested at a high concentration of 2.0 mg/mL. With 
less than 5 % of KB cell proliferation was affected, blank micelles could be practically 
non-toxic to KB cells at a high tested concentration of 2.0 mg/mL. Figure 4.6 shows that 
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the cell viability of KB reduces at higher micelle concentration. It can be seen that 
TAT/FOL-modified micelles are the most efficient in cancer treatment than the 
unmodified or FOL-modified micelles. As presented in Table 4.3, the IC50 of DOX- 
micelles and PTX-micelles are at 3.873 µM and 0.79 µM respectively. And these values 
are reduced to 1.084 µM and 0.246 µM for DOX- TAT/FOL and PTX-TAT/FOL 
micelles. In short, the required dosage to kill 50% KB cells of the drug loaded-TAT/FOL 
micelles is approximately one third of that of the drug loaded-micelles. This result 
suggests that the presence of FOL and TAT on the micelles can promote the effectiveness 
of the drug-loaded micelles.   
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Figure 4.6 Effect of FOL and TAT/FOL modifications on the cytotoxicity of drugs-
loaded micelles to KB cell treatment as investigated using (A) DOX- loaded micelles and 
(B) PTX-loaded micelles.  
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The current TAT/FOL system shows higher efficiency than the previous system [137] 
using TAT-modified micelles based on TAT-PEG-phosphatidylethanolamine, which only 
shows less than 2 times enhancement compared to the non-modified micelles. As for a 
reported TAT-modified pH-sensitive micelle system, the TAT-modified micelles show 
~0.3 to 1.8 times enhancement at pH conditions ranging 6-7 compared to the non-
modified micelles [271].  
 
Table 4.3 Effect of micellar surface modifications to the cancer treatment efficiency.  
Micelles  IC50 (µM) 
DOX-micelles  3.873 
DOX-FOL micelles  2.556 
DOX-TAT/FOL micelles  1.084 
PTX- micelles  0.790 
PTX-FOL micelles  0.446 
PTX-TAT/FOL micelles  0.246 
 
The cytotoxicity effect of single drug encapsulated micelles has been characterized in this 
work as parameters to determine the CI values of co-delivery of DOX- FOL micelles & 
PTX-FOL micelles, co-delivery of DOX- TAT/FOL micelles & PTX-TAT/FOL micelles, 
DOX/PTX-FOL micelles and DOX/PTX-TAT/FOL micelles in the subsequent studies.  
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4.3.6 Synergistic effect of the co-delivery of DOX- loaded micelles and PTX-loaded 
micelles 
Co-delivery of two single drug-loaded micelles (Figure 4.1A and 4.1B) can potentially be 
a more flexible method to obtain the synergistic treatment compared with the dual drugs-
loaded micelles (Figure 4.1C and 4.1D). Because the combined ratios in the co-delivery 
of two single drug-loaded micelle system can be easily varied for specific treatment. In 
this study, two systems with FOL modification (DOX-FOL micelles & PTX-FOL 
micelles) and TAT/FOL modification (DOX-TAT/FOL micelles & PTX-TAT/FOL 
micelles) at molar ratio of DOX/PTX of 1/0.2 have been used to demonstrate the 
possibility of using the two single drug-loaded micelles to co-deliver DOX and PTX at 
synergistic effect and the enhancement of the TAT/FOL modification compared to FOL 
alone. The co-delivery of two single drug loaded micelles was noted as DOX micelles & 
PTX micelles_x/y at molar ratio of DOX/PTX at x/y. 
 
Table 4.4 IC50 of different micellar treatments: (1) co-delivery of two singe drug loaded 
micelles at the ratio of DOX/PTX at 1/0.2, and (2) dual drugs-loaded micelles at the ratio 
of DOX/PTX at 1/0.25.  
Treatment IC50 (µM) 
Co-delivery systems 
DOX-FOL micelles & PTX-FOL 
micelles_1/0.2 
0.469/0.094 
DOX-TAT/FOL micelles & PTX-TAT/FOL 
micelles_1/0.2 
0.219/0.044 
Dual drugs-loaded systems DOX/PTX(1/0.25)-FOL micelles 0.416/0.104 




Figure 4.7 Cytotoxicity dose response of KB cells with various DOX and TAM delivery strategies: (A) the co-delivery of two single 
drug-loaded micelles (Fig. 1A & 1B) at DOX/PTX ratio of 1/0.2, and (C) the dual drugs-encapsulated micelles at the encapsulated 
DOX/PTX ratio of 1/0.25. Synergistic effects of (B) the co-delivery of DOX- loaded micelles & PTX-loaded micelles treatments and 
(D) the dual DOX/PTX-loaded micelles were presented as the CI values as the function of cell viability. 
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The higher cancer treatment efficacy of the system with TAT/FOL modification 
compared to FOL alone is shown as the lower required treatment dose at the same 
treatment effect (Figure 4.7A). The required dose to kill 50% KB cells of the DOX-
TAT/FOL micelles & PTX-TAT/FOL micelles_1/0.2 system is more than 2 times lower 
than that of DOX-FOL micelles & PTX-FOL micelles_1/0.2 system (Table 4.4). Figure 
4.7B presents the CI values of different combinations as the function of cell viability. 
Obviously, both co-delivery of single drug-loaded micelle systems show the synergistic 
effect with all CI values < 1 for the wide range of treatment concentrations which is the 
same phenomenon as observed in the DOX and PTX combination (Section 4.3.1). 
 
4.3.7 Synergistic effect of dual drugs-loaded micelles and the surface modifications  
DOX/PTX-FOL micelles and DOX/PTX-TAT/FOL micelles at the synergistic 
combination of DOX/PTX (approximately 1/0.25) have been studied to investigate the 
effects of dual DOX/PTX encapsulation as well as surface modification in KB cell 
treatment (Figure 4.1C and 4.1D). As shown in Figure 4.7C, dual DOX/PTX micelles 
with TAT/FOL modification show higher cancer treatment efficiency than FOL-modified 
micelles. The IC50 values of DOX/PTX (1/0.25)-FOL micelles and DOX/PTX (1/0.25)-
TAT/FOL micelles are 0.416/0.104, 0.172/0.043 respectively as tabulated in Table 4. 
Based on the IC50 values, the addition of TAT enhances the activity of the DOX/PTX 
(1/0.25)-FOL micelles to approximate 2.4 times. This observation is in consistent to the 
data of TAT/FOL vs. FOL only modification in single drug-loaded micelle delivery 
(Section 4.3.5) and co-delivery of two single drug-loaded micelles (Section 4.3.6). 
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The synergistic effects of the DOX/PTX-FOL micelles and DOX/PTX-TAT/FOL 
micelles are calculated following the analysis of the cytotoxicity curves of the single drug 
treatments (i.e., DOX-FOL micelles, DOX-TAT/FOL micelles, PTX-FOL micelles and 
PTX-TAT/FOL micelles) in Figure 4.6 and the cytotoxicity curves of the combination 
treatments in Figure 4.7C. The CI values which are computed and presented in Figure 
4.7D show the synergistic effect of the two dual drugs-loaded micelle systems. In this 
study, in vitro cytotoxicity results show that the co-delivery of two single drug-loaded 
micelles and the dual drugs-loaded micelles exhibit the same synergistic effect to KB 
cells. However, the effect of the two methods may be different in vivo application as the 
micelles are circulated in the body’s blood vessel before being delivered to the targeted 
tumors.  The co-delivery of two single drug-loaded micelles may leads to the change in 
the designed drug ratio at the targeted tumors. However, the delivery of dual drugs-
loaded micelles has higher possibility in maintaining the initial drug ratio at the targeted 
tumors because the two drugs are encapsulated at the synergistic ratio into the same 
carrier. Therefore, the dual-drug loaded micelle system with FOL and TAT modifications 
is a better method for cancer treatment.  
 
4.4 Conclusions 
Synergistic effects of DOX and PTX at several fixed-ratios have been investigated for 
mouth epidermal carcinoma treatment (KB cells). The result suggests that DOX-based 
combination at molar ratio of DOX/PTX at 1/0.2 may be the optimal ratio for KB cell 
treatment. To reduce the side-effects and control the release, the drugs have been 
encapsulated into micelles. DOX and PTX are encapsulated into micelles and delivered 
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by two methods which are (1) co-delivery of two single drug-loaded micelles or (2) dual 
drugs-loaded micelles. The two methods show the same synergistic effect but they 
contain their own advantage and limitation. For the co-delivery of two single drug-loaded 
micelles, the combination ratio could be easily varied for specific treatment with the 
limitation of maintaining the designed ratio in vivo treatment. The dual drugs-loaded 
micelles have higher possibility in maintaining the initial drug ratio for in vivo 
application which could overcome the limitation of the co-delivery of two single drug-
loaded micelles. However, the variation of drug ratios of the two drugs in the dual drugs-
loaded micelles would require further optimization for specific applications. Moreover, 
the addition of a low amount of TAT (about 2.5%) onto the micelles has been shown the 
enhancement in the cancer treatment by about 2 times.  
 
This chapter has investigated the optimal synergistic drug ratio in the combination of two 
chemodrugs (DOX and PTX) and co-delivered this synergistic combination using 
TAT/FOL micelles. In the next chapter, the combination of a hormonal agent (TAM) and 
a chemodrug (PTX) is investigated for breast cancer treatment. The work in the following 
chapter addresses objective 3 in chapter 1. 
 95 
CHAPTER 5. Dual-functionalized micellar system for 
synergistic delivery of hormone therapeutic and 
chemotherapeutic agents for breast cancer treatment 
 
5.1 Introduction  
Breast cancer is the leading cancer in women global with an estimate of 226 thousands 
new cases in the United States in 2012, which is approximate 29 % among women 
cancers. The two leading treatments for breast cancer patients are chemotherapy and 
hormone therapy. Chemotherapy uses cytotoxic drugs to kill cancer cells all over the 
patient’s body. There are different types of chemotherapy drugs for breast cancer therapy, 
such as: (1) anthracyclines (doxorubicin, epirubicin) that deform DNA structure of cancer 
cells, (2) taxanes (paclitaxel, docetaxel) that prevent cancer cells from dividing, or (3) 
alkylating agents (cyclophosphamide) that target DNA of cancer cells. Hormone therapy 
is specifically used for breast cancer patients with hormone receptor-positive tumors. 
Various types of hormone therapy classes are: (1) selective estrogen–receptor modulators 
(tamoxifen, raloxifene, toremifene) that block estrogen receptors in breast cancer cells 
and  starve them, (2) aromatase inhibitors (exemestane, anastrozole, megestrol, letrozole) 
that suppress production of estrogen in adrenal glands, or other hormonal therapies 
(goserelin acetate, fulvestrant) treat breast cancers that are dependent on estrogen for 
survival. 
 
Besides the traditional single drug therapy, the therapy with the combination of two or 
more anticancer drugs has been widely applied to treat cancer diseases due to its 
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advantages compared to single agent therapy which has been limited due to the toxicity 
of the high drug dosage, the heterogeneity of cancer cells and the drug resistance [212-
215]. Therefore, combination therapy has been more preferable thanks to its wide 
application for different cancer patients and perhaps its lower toxicity at the required 
effect. In addition, synergistic combinations could promote the response rate compared to 
single drugs, resulting in the better cancer cell treatment effect. 
 
 
Figure 5.1 Molecular structures of two anticancer drugs and their pharmacodynamics in 
cancer cells: (A) tamoxifen (TAM) and (B) paxlitaxel (PTX). 
 
This chapter demonstrates new drug delivery approaches for breast cancer treatment 
based on the synergistic effect of drug combinations and the higher treatment efficacy of 
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carrier modifications. A common chemotherapy drug – paclitaxel (PTX) and a first 
widely used hormone therapy drug – tamoxifen (TAM) were used as combined 
treatments in this study. PTX promotes microtubule assembly from tubulin dimmers, 
stabilizes microtubules by preventing depolymerization [12] as shown in Figure 5.1A. 
While TAM prevents the effects of estrogen to breast cancer cells [11] as insulated in 
Figure 5.1B. Therefore, a pair of TAM and PTX would be promising synergistic 
combinations for breast cancer treatment with higher efficacy than the treatment with 
TAM or PTX alone. Prior to the encapsulation, the effects of different combinations of 
the two drugs were investigated to find out the synergistic ratio as a guide composition 
for subsequent drug-encapsulating studies.  Mixed polymeric micelles based on PLGA-
PEG, PLGA-PEG-FOL and PLGA-PEG-TAT copolymers were employed as carriers for 
TAM and PTX delivery. The resultant drug-loaded micelles have hundreds nanometer 
size and exhibit targeting moiety (FOL) and cell penetrating peptide (TAT) on the 
surfaces. Therefore, they selectively accumulate into cancer cells with high binding 
affinity by active delivery that overcomes the limitations of free drugs (PTX and TAM) 
delivery (Figure 5.2).  
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Figure 5.2 The free drugs (TAM and PTX), which have small molecular weight and is 
normally cleared rapidly from the blood, accumulate in both normal cells and cancer 
cells. While the micelles modified by a targeting moiety (FOL, in red) and a cell 
penetrating peptide (TAT, in yellow) at hundreds nanometer size accumulate largely in 
the cancer cells. 
 
The combined TAM and PTX treatments using micelles as carriers were studied with two 
methods. The first method was carried out by co-delivery of two single drug-loaded 
micelles (Figure 5.3A). The second method demonstrated the effect of dual drugs-loaded 




Figure 5.3 Cancer treatment by a synergistic combination of tamoxifen (TAM) and 
paclitaxel (PTX) utilized the drug delivery technology. Two treatment approaches: (A) 
co-delivery two drug-loaded micelles,  TAM- TAT/FOL micelles & PTX-TAT/FOL 
micelles and (B) dual drugs-loaded micelles, TAM/PTX-TAT/FOL micelles. 
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5.2 Experimental section 
5.2.1 Materials 
Three block copolymers poly(D,L-lactide-co-glycolide)-poly(ethylene glycol) (PLGA-
PEG), poly(D,L-lactide-co-glycolide)-poly(ethylene glycol)-folate (PLGA-PEG-FOL) 
and poly(D,L-lactide-co-glycolide)-poly(ethylene glycol)-TAT (PLGA-PEG-TAT) were 
synthesized for micellar fabrication as presented in Chapter 3. Tween 80, 3-[4,5-
dimethylthiazolyl-2]-2,5-diphenyl tetrazolium bromide (MTT), tamoxifen (TAM) and 
paclitaxel (PTX) were all purchased from Sigma-Aldrich (USA). Methanol, 
dichloromethane (DCM), acetonitrile (ACN), tetrahydrofuran (THF), chloroform, diethyl 
ether were purchased from Tedia (USA). Triethylamine (TEA) was acquired from Alfa 
Aesar. Folate-free RPMI 1640 medium, fetal bovine serum (FBS), Trypsin-EDTA and 
penicillin-streptomycin were obtained from Invitrogen (USA). Estrogen receptor-positive 
human breast cancer cell line (MCF-7) was purchased from ATCC (USA). All chemicals 
were used directly without further purification. 
 
5.2.2 Preparation and characterization of PTX and TAM loaded polymeric micelles 
Drug-loaded micelles were prepared by three steps: (1) dissolving of hydrophobic drugs 
(i.e., PTX and/or TAM) and mixture of three polymers as mentioned above in DCM, (2) 
evaporating DCM to form a thin film matrix and (3) forming micelles by adding water 
into the film under stirring. Further purification by dialyzing against de-ionized (DI) 
water was carried to remove un-encapsulated drug. 
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The hydrodynamic size and zeta potential of polymeric micelles were measured at 25°C 
by dynamic light scattering (DLS) (NanoSizer, Malvern Instruments, UK). Aqueous 
micelle solutions were prepared using deionized water. The concentration of polymeric 
micelles was kept at 1 mg/ml. The micelle solutions were filtered through a 0.80 µm 
cellulose membrane filter before measurements. The average values were calculated from 
at least 3 measurements performed on each samples.  
 
The amount of TAM and PTX in micelles was analyzed using a high performance liquid 
chromatography (HPLC, Agilent 1200, USA) equipped with a ZORBAX 300SB-C18 
column. The micelles were dissolved in DCM to destroy the micellar structure and 
dissociate the drugs from the polymers. Subsequently, DCM solvent was evaporated 
completely before the mobile phase solutions were added into the samples. The PTX-
loaded samples were then flowed through the column with a solution of acetonitrile/water 
(50/50, v/v) as a mobile phase, and TEA/water/methanol (1/11/89, vol%) was used as the 
mobile phase for  TAM-loaded sample elution. The TAM and PTX were detected with a 
UV detector at 227 nm and 265 nm wavelengths respectively. Standard curves of TAM 
and PTX were established at concentration form 0 to 50 µM/mL for the quantitative 
calculation of these drugs. 
 
5.2.3 In vitro release study 
Micelle solutions with concentration of 2 mg in 1 ml of PBS with the addition of 0.05 
w/v% Tween 80 were transferred to dialysis tube (MWCO: 2,000 Da) and dialyzed 
against 3 ml 0.05 w/v% of Tween 80 in PBS in a tube at 37°C with shaking at 100 
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rev/min. Drug release at different time intervals was measured by quantitatively 
analyzing of the released drugs in the dialysis solution. The released drugs in the dialysis 
solutions were firstly extracted into the organic phase for HPLC analysis by adding equal 
volume of DCM into the aqueous solutions. The solutions were further mixed for 24 h 
before discarding the aqueous solution for the completion of drugs extraction into the 
organic phase. TAM and PTX were quantitatively determined by HPLC as used for the 
determination of the loading amount of TAM and PTX in micelles as described in the 
previous section. 
 
5.2.4 In vitro cellular uptake 
The cell target and cell penetration tests of micelles with and without TAT/FOL were 
carried out in MCF-7 cells by labeling the micelles with C6.  The cells were cultured in 
12 mm round glass coverslips placed in 24-well plates for 1 day. Cells were then treated 
with 30 µM C6-loaded micelles for 3 h. Subsequently, the cells were washed 3 times with 
cold PBS, fixed with 4% cold paraformaldehyde for 30 min at room temperature, and 
washed with PBS again. The fixed cells on coverslips were observed under confocal 
microscope (Nikon C1, Japan) at excitation wavelength of 480 nm and emission 
wavelength of 590 nm. 
 
5.2.4 In vitro cytotoxicity study 
The inhibiting ability of free drugs and drug-loaded micelles to breast cancer tumor 
proliferation was evaluated using MCF-7 cells with MTT viability assay. Cells cultured 
in free folic RPMI media supplemented with 10% FBS and 1% penicillin-streptomycin at 
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37°C in humidified environment of 5% CO2 were seeded onto 96-well plates at a seeding 
density of 10,000 cells/well and incubated for 2 days to permit cell attachment. The cells 
were then treated with free drugs or drug-loaded micelles at different concentrations. 
After 3 days of incubation with drug solutions, the cell viability was measured by MTT 
assay as described in Chapter 3.   
 
5.2.5 Median-effect analysis  
Effects of the combined drug treatment compared to single drug treatments were 
analyzed by a Calcusyn software (Biosoft, USA) derived from the Chou and Talalay’s 
principle [232, 233] to provide quantitative information on the interaction of the 
combined drugs. The combination index (CI) of the combined two drugs was determined 
based on the described equation in Chapter 2 (eq. 2-2).  
 
5.3 Results and discussion 
5.3.1 In vitro cytotoxicity interaction between free tamoxifen (TAM) and free 
paclitaxel (PTX)  
Given that each type of anticancer drugs has a different working mechanism, the strategy 
of combining two drugs together is to capitalize on the synergistic efficacy enhancement 
arisen from executing both mechanisms simultaneously. However, different dose 
combinations can results in additive, antagonistic or synergistic treatment effects. 
Therefore, the molar ratios of TAM to PTX were first studied at 1/0, 1/0.5, 1/1, 0.5/1, 
0.35/1, 0.2/1 respectively. As shown in Figure 5.4A, the increase in PTX ratio of the 
combined TAM/PTX treatments leads to the lower cell viability at the same TAM 
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concentration. This indicates that increasing PTX of the TAM/PTX ratio from 1/0 to 1/1 
can result in the higher treatment efficacy. Similar effect can be observed when 
increasing TAM of the TAM/PTX ratios (Figure 5.4B). When increasing the TAM/PTX 
ratios from 0/1 to 0.2/1 and 0.35/1, the cell viability stays unchanged. Further increment 
to 0.5/1 results in the decrease in cell viability. This indicates that the combined 
TAM/PTX treatments at ratios of 0.2/1 and 0.35/1 have antagonistic effect while 
TAM/PTX_0.5/1 may give synergistic effect. The higher IC50 values of TAM/PTX_0.2/1 
and TAM/PTX_0.35/1 (Table 5.1) further demonstrate the antagonistic effect of these 
ratios. Other combined ratios may exhibit synergistic effect, as the IC50 values of these 
ratios are equal or lower than that of free TAM or free PTX. 
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Figure 5.4 In vitro cytotoxicity study of combinations of free TAM and free PTX on 
MCF-7 cells: (A) MCF-7 viability vs. TAM concentration as increasing PTX in the 
combined TAM/PTX from 0 - 50% and (B) MCF-7 viability vs. PTX concentration as 
increasing TAM in the combined TAM/PTX from 0 - 33%. The combined treatment 
effects were presented as the combination index (CI) of different combined ratios versus 




The Calcusyn software derived from median-effect principle was employed to provide 
more quantitative information on the effect of the combined treatments. The effects of the 
combinations are presented as the CI values as the function of factional effect of the 
treatment to the cells. This is the common method to present the effect of the combined 
treatments as reported by previous studies [11, 219]. It can be seen from Figure 5.4C that 
the TAM/PTX_1/1 treatment gives the synergistic effect over the whole range of 
concentrations. TAM/PTX_1/0.5 and TAM/PTX_0.5/1 treatments result in the 
synergistic effect at low concentrations while antagonistic at high treatment 
concentrations. Lower the TAM/PTX ratio (TAM/PTX_0.35/1 and TAM/PTX_0.2/1) 
leads to the antagonistic effect for all treatment concentration. Therefore, TAM/PTX_1/1 
combination was used as the optimal synergistic composition for drug-encapsulated 
studies. 
 
Table 5.1 IC50 of different treatment compositions of free TAM and free PTX to MCF-7 
cells.  
Treatment compositions  IC50 (µM)  
TAM/PTX_1/0 (free TAM) 7.74 
TAM/PTX_1/0.5  5.40/2.70 
TAM/PTX_1/1  2.80/2.80 
TAM/PTX_0.5/1  2.76/5.52 
TAM/PTX_0.35/1  2.80/8.00 
TAM/PTX_0.2/1  2.10/10.50 
TAM/PTX_0/1 (free PTX) 9.16 
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5.3.2 Characterization of drug-loaded polymeric micelles  
Physical properties of the drug-loaded micelles were analyzed by a DLS to obtain their 
hydrodynamics size and surface zeta potential which are important factors for the 
stability, prolong circulation, and efficacy of the drug delivery carriers [273, 274]  . All 
drug-loaded micelles used in this study was found to have less than 200 nm in size and 
negative zeta potential (Table 5.2) that are suitable for drug delivery as indicated by 
previous studies [273].    
 
Table 5.2 Characterization of single drug-loaded micelles and dual drugs-loaded micelles 
with TAT/FOL modification.  








TAM-TAT/FOL micelles  1.21 56.5 161.8 -3.5 
PTX-TAT/FOL micelles  1.12 52.3 132.8 -10.6 
TAM/PTX(0.6/1)-TAT/FOL 
micelles 





The drug loading content (DLC) of the single-drug loaded micelles are approximately 
1.2% (Table 5.2). Although the DLC of the two single drug loaded micelles ( TAM-
TAT/FOL micelles and PTX-TAT/FOL micelles) are almost equal, the release rate of 
TAM from  TAM-TAT/FOL micelles is faster than the release rate of PTX from PTX-
TAT/FOL micelles (Figure 5.5A). The faster release rate of TAM compared to PTX from 
the micelles may due to (i) the higher diffusivity of TAM through the micellar shell 
caused by the its smaller size compared to that of PTX and (ii) the faster dissociation of 
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TAM from the hydrophobic core of micelles caused by the less hydrophobic nature of 
TAM compared to PTX.  
 
Based on the in vitro cytotoxicity study of the TAM/PTX ratios, the synergistic effect 
was observed at the treatment of TAM/PTX_1/1. Therefore, co-delivery of two single 
drug-loaded micelles was carried at the molar ratio of released TAM/released PTX at 
approximately 1/1 to obtain the synergistic effect of the combination. Figure 5.5A shows 
that the % release of TAM/PTX from the micelles is approximately 1.7/1. In addition, the 
DLC of the two single drug loaded micellar systems are similar. Co-delivery of two 
single drug-loaded micelles (TAM-TAT/FOL micelles & PTX-TAT/FOL micelles) was 
studied at the molar ratio of approximately 0.6/1 (presented as TAM-TAT/FOL micelles 
& PTX-TAT/FOL_0.6/1) to obtain the molar ratio of released TAM/ released PTX at 1/1. 
Similarly, the dual drugs-loaded micelles (TAM/PTX-TAT/FOL micelles) were prepared 
so that the dual drugs-loaded micelles could be formed at the TAM/PTX ratio of 
approximately 0.6/1 (presented as TAM/PTX(0.6/1)-TAT/FOL micelles). From the 
release profile of TAM/PTX(0.6/1)-TAT/FOL micelles in Figure 5.5B, the percentage 
release of TAM (calculated as (molar of released TAM/molar of loaded TAM)*100%) 
from the micelles is higher than that of PTX. This observation is in agreement with the 
release rate of single drug loaded micelles (Figure 5.5A). Combining the percentage 
release of TAM and PTX with the loading contents of TAM and PTX in the dual micellar 
system, the molar release of TAM to PTX is nearly 1 as shown in Figure 5.5B. This is the 
synergistic TAM/PTX ratio for the MCF-7 cells as determined in the previous section. 
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Figure 5.5 In vitro release profiles of TAM and PTX from (A)  TAM-TAT/FOL micelles 
and PTX-TAT/FOL micelles, and (B) TAM/PTX(0/6/1)-TAT/FOL micelles in PBS (pH 
7.4) at 37ºC. The experiments were conducted in triplicate. The standard deviation is less 
than 15%. 
 
5.3.3 Enhancement of drug-loaded micelles with the surface modification using 
combined TAT and FOL  
The modification of carrier’s surface with FOL has demonstrated enhanced targeting 
property and cancer treatment effect [259, 275] including our previous study [257]. To 
further enhance the treatment efficiency, TAT peptide was utilized in this study since 
they are capable of transporting attached macromolecules from extracellular space 
through the cell membrane into cytoplasm in both in vitro and in vivo studies [138, 159, 
172, 246]. The increase in cancer treatment efficacy of the drug-loaded micellar system 
with the modification of TAT and FOL was demonstrated by the comparison between 
non-modified micelles (prepared from PLGA-PEG copolymer) and TAT/FOL micelles 
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(prepared from 10% PLGA-PEG-TAT, 10% PLGA-PEG-FOL and 80% PLGA-PEG 
copolymers). 
 
Figure 5.6 Confocal images of MCF-7 cells after incubation with various C6-loaded 
micellar systems. 
 
First, in vitro cellular uptake of different surface modified micelles was observed in 
breast cancer cells (MCF-7). As shown in Figure 5.6, the fluorescence intensity in MCF-7 
cells increases when micelles are modified with targeting (FOL) or penetrating (TAT) 
moiety. The strongest fluorescence intensity is observed for the cells treated with 
combined TAT and FOL modified micelles (TAT/FOL micelles). This observation 
indicates that the modification of micelles potentially improves the treatment efficacy of 
the drug delivery system. Multi-modification system may exhibit the highest treatment 
efficacy among these micellar systems.   
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Figure 5.7 Comparisons of in vitro MCF-7 cell viability that responds to the treatments with (A) TAM micelles,  TAM- TAT/FOL 
micelles and co-delivery of  TAM- TAT/FOL micelles & PTX-TAT/FOL micelles_0.6/1; (B) PTX micelles, PTX-TAT/FOL micelles 
and co-delivery of  TAM- TAT/FOL micelles & PTX-TAT/FOL micelles_0.6/1. The synergistic effect of co-delivery of TAM- 
TAT/FOL micelles & PTX-TAT/FOL micelles_0.6/1 compared to TAM- TAT/FOL micellar or PTX-TAT/FOL micellar treatments 
was demonstrated as the CI values < 1 (C).  
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Furthermore, in vitro cytotoxicity study was carried out to investigate the anticancer 
effect of combined TAT/FOL micelles onto MCF-7 cells. The toxicity of all blank 
micelles was measured at a concentration of 2.0 mg/mL. The polymer concentration used 
in the blank micelle tests was higher than the concentration of polymers in all 
cytotoxicity tests with the presence of drug(s). Blank micelle tests indicate that micelles 
at concentration of 2.0 mg/mL were practically non-toxic to MCF-7 cells. Cell viability 
after non-modified micellar treatments (TAM micelles and PTX micelles) and TAT/FOL-
modified micellar treatments (TAM-TAT/FOL micelles and PTX-TAT/FOL micelles) 
are shown in Figure 5.7A and 5.7B. It is obviously that the treatment with TAM-
TAT/FOL micelles or PTX-TAT/FOL micelles is more efficient than the treatments with 
TAM micelles or PTX micelles as the much lower cell viability is observed at the same 
treatment concentration.  
 
Table 5.3 IC50 values of different micellar systems to MCF-7 cells.   
Treatment IC50 (µM) 
Single treatment 
TAM micelles  10.61 
PTX micelles  20.70 
TAM -TAT/FOL micelles  3.01 
PTX-TAT/FOL micelles  5.93 
Co-delivery  treatment TAM-TAT/FOL micelles & PTX-TAT/FOL micelles_0.6/1  0.90/1.50 
Dual encapsulated treatment TAM/PTX(0.6/1)-TAT/FOL micelles 0.85/1.41 
 
As shown in Table 5.3, the IC50 of TAM micelles and PTX micelles are 10.61 µM and 
20.70 µM respectively. With the addition of TAT and FOL onto the carrier surface, these 
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values are reduced to 3.01 µM and 5.93 µM, which is approximate 3.5 times lower than 
the IC50 of TAM micelles and PTX micelles. Compared with previous studies using TAT 
for micellar surface modification [137, 271] that exhibited less than 2 times enhancement 
compared to the non-modified micelles. The TAT/FOL modified micelles in this study 
performs better in promoting the effectiveness of the drug-loaded micelles.   
 
5.3.4 Synergistic effect of the co-delivery of TAM-TAT/FOL micelles and PTX-
TAT/FOL micelles 
The preliminary studies in Sections 5.3.1 and 5.3.3 show that: (1) the treatment with the 
combination of two drugs TAM and PTX at ratio of 1/1 gives synergistic effect and (2) 
drug-loaded TAT/FOL micelles are more efficient than drug-loaded non-modified 
micelles. By utilizing the advantages of both mentioned methods, the co-delivery of 
TAM-TAT/FOL micelles and PTX-TAT/FOL micelles (Figure 5.3A) at the molar ratio 
of TAM/PTX of 0.6/1 (presented as TAM-TAT/FOL micelles & PTX-TAT/FOL 
micelles_0.6/1) was investigated.  TAM-TAT/FOL micelles & PTX-TAT/FOL micelles 
was co-delivered at the ratio of 0.6/1 because this co-delivery ratio could provide the 
release amount of TAM/PTX of 1/1 to the breast cancer cells as discussed in Section 
5.3.2.  
The treatment effect of this system was compared with the TAM-TAT/FOL micellar or 
PTX-TAT/FOL micellar systems by in vitro cytotoxicity study.  The required TAM and 
PTX concentrations of TAM-TAT/FOL micelles & PTX-TAT/FOL micelles_0.6/1 are 
lower than that of TAM-TAT/FOL micelles (Figure 5.6A) and PTX-TAT/FOL micelles 
(Figure 5.6B) to provide the same treatment efficacy respectively. Quantitatively, IC50 
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values of TAM of co-delivered  TAM-TAT/FOL micelles & PTX-TAT/FOL_0.6/1 is 0.9 
µM and 3.3 times lower than that of  TAM-TAT/FOL micelles (3.01 µM) (Table 5.3). 
Similarly, IC50 value of PTX of co-delivered TAM-TAT/FOL micelles & PTX-
TAT/FOL_0.6/1 is approximate one quarter of that of PTX-TAT/FOL micelles. To 
further confirm the synergistic effect of this treatment method, the CI values of the 
treatment was calculated from the in vitro cytotoxicity experimental data of TAM-
TAT/FOL micellar treatment, PTX-TAT/FOL micellar treatment and co-delivered TAM-
TAT/FOL micelles & PTX-TAT/FOL_0.6/1 treatment using the Calcusyn software. 
From Figure 5.6C, the Cl values of less than 1 for all the fractional effect prove the 
synergistic effect of this co-delivery system compared with the TAM-TAT/FOL micellar 
and PTX-TAT/FOL micellar systems. 
 
5.3.5 Synergistic effect of dual drugs-loaded micelles (TAM/PTX-TAT/FOL 
micelles) 
In this section, we tested the enhancement potential of co-encapsulating TAM and PTX 
into the same TAT/FOL micelle, a dual drugs-loaded micelle system. Similar to the 
TAM-TAT/FOL micelles & PTX-TAT/FOL micelles_0.6/1 system shown in Section 
5.3.4, the two drugs were loaded into this dual drugs micellar system at the TAM/PTX 





Figure 5.8 Comparisons of in vitro MCF-7 cell viability that responds to the treatments 
with (TAM-TAT/FOL micelles and dual encapsulated TAM/PTX(0.6/1)-TAT/FOL 
micelles; (B) PTX-TAT/FOL micelles and dual encapsulated TAM/PTX(0.6/1)-
TAT/FOL micelles. The synergistic effect of the dual encapsulated treatment compared 
to TAM-TAT/FOL micellar or PTX-TAT/FOL micellar treatments was demonstrated as 
the CI values < 1 (C).  
 
The effects of the TAM/PTX(0.6/1)-TAT/FOL-micelles compared with TAM-TAT/FOL 
micelles and PTX-TAT/FOL micelles were firstly shown as the cell viability after 
treatment at different treatment concentrations of TAM (Figure 5.7A) and PTX (Figure 
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5.7B). From the two figures, the synergistic effects are observed from the lower cell 
viability of TAM/PTX(0.6/1)-TAT/FOL-micelles compared with that of TAM-TAT/FOL 
or PTX-TAT/FOL at the same TAM or PTX treatment concentration respectively. In 
Table 3, the IC50 of TAM/PTX(0.6/1)-TAT/FOL-micelles are 0.85 µM of TAM and 1.41 
µM of PTX, approximately 3.5 and 5.2 times lower than the IC50 of  TAM- TAT/FOL 
micelles and PTX-TAT/FOL micelles respectively. Moreover, Fig. 7C shows that all the 
CI values of TAM/PTX(0.6/1)-TAT/FOL-micelles are below 1, indicating the synergistic 
effect of the dual treatment as proven in previous studies [11, 219]. By utilizing the 
advantages of dual drugs-treatment and TAT/FOL modification, this newly developed 
system, TAM/PTX(0.6/1)-TAT/FOL micelles, shows much higher efficacy to MCF-7 
treatment at IC50 of 0.85 µM T/1.41 µM PTX compared with the IC50 of traditional 
treatments of free TAM (7.74 µM) or free PTX (9.16 µM), or the single drug-loaded non-
modified TAM (10.61 µM) micelles or PTX micelles (20.70 µM). 
 
In this research work, we have demonstrated two systems, the co-delivery of two single 
drug-loaded micelles (TAM-TAT/FOL micelles & PTX-TAT/FOL_0.6/1) and the dual 
drugs-loaded micelles (TAM/PTX(0.6/1)-TAT/FOL micelles). The co-delivery of two 
single drug-loaded micelles is a flexible system for various treatments required different 
drug ratios. In contrast, the drug ratio of the dual drugs-loaded micelles is fixed. In vitro 
cytotoxicity results show that exhibit the same synergistic effect to MCF-7 cells. 
However, the effect of the two methods may be different in vivo application as the 
micelles are circulated in the body’s blood vessel before being delivered to the targeted 
tumors. The co-delivery of two single drug-loaded micelles may leads to the change in 
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the designed drug ratio at the targeted tumors. However, the dual drugs-loaded micelles 
have higher possibility in maintaining the initial drug ratio at the targeted tumors because 
the two drugs are encapsulated at the synergistic ratio into the same carrier. Therefore, 
the dual-drug loaded micelle system with FOL and TAT modifications is a better method 
for cancer treatment.   
 
5.4 Conclusions 
This study demonstrated the synergistic effect of the combined TAM and PTX at the ratio 
of 1/1 to breast cancer treatment. Further studies based on micellar technology for drug 
delivery were carried out to utilize (1) the synergistic effect of the combined TAM and 
PTX, (2) the advantage of micellar system to reduce the side-effects and control the 
release, and (3) the increase in penetrating and targeting efficacy of TAT/FOL modified 
system. Therefore, two newly developed systems were investigated in this work for 
breast cancer treatment: co-delivery of two single drug-loaded TAT/FOL modified 
micelles (TAM-TAT/FOL micelles & PTX-TAT/FOL micelles_0.6/1) and dual drugs-
loaded TAT/FOL modified micelles (TAM/PTX(0.6/1)-TAT/FOL micelles). The two 
methods show the same synergistic effect but they contain their own advantage and 
limitation. For the co-delivery of two single drug-loaded micelles, the combination ratio 
could be easily varied for specific treatment with the limitation of maintaining the 
designed ratio in vivo treatment. The dual drugs-loaded micelles have higher possibility 
in maintaining the initial drug ratio for in vivo application which could overcome the 
limitation of the co-delivery of two single-drug-loaded micelles. However, the variation 
of drug ratios of the two drugs in the dual drugs-loaded micelles would be the limitation 
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for this system. Therefore, further optimization needs to be carried for specific 
applications. 
 
Chapter 4 and Chapter 5 have demonstrated the co-encapsulation and co-delivery of 
synergistic hydrophobic drug combinations into micellar systems. To prove that micelles 
are not only able to co-encapsulate hydrophobic drugs. But they would be able to carry 
hydrophilic drugs if the suitable polymers are used to obtain strong interaction between 
drugs and polymers. Next chapter describes the co-encapsulation of cisplatin (CDDP) and 
DOX (in hydrophilic form DOX.HCl). The work in the next chapter addresses objective 
4 in Chapter 1. 
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CHAPTER 6. Targeting delivery of a synergistic combination 
of doxorubicin and cisplatin with polymer-drug complex 
micellar systems 
 
6.1 Introduction  
Cisplatin (CDDP) is a first generation an platinum (Pt)-based anticancer drug that was 
first invented in 1965 [30].  CDDP has been demonstrated as a successful drug in 
inhibiting the growth of various types of cancers such as lung, ovarian, bladder, breast, 
testicular, head and neck cancers. Despite the high anticancer activity of CDDP, its 
application is limited due to the serious side effects including acute and chronic 
nephrotoxicity, myelosuppression [13]. In addition, CDDP exhibits some other 
unfavorable properties including poor water solubility, fast clearance [276], intrinsic or 
acquired tumor resistance [277]. Due to the rapid development of drug resistance in the 
tumor cells against CDDP, the combined therapy using CDDP (a platinum-based class) 
and non-platinum-based drugs are frequently used to archive higher chemotherapy 
efficacy [278-281]. Among many non-platinum-based drugs, doxorubicin (DOX), which 
works by binding to DNA and inhibiting nucleic acid synthesis of cells, has been 
commonly used together with CDDP in the combination therapy. Although the combined 
CDDP and DOX therapy has been demonstrated in phase III clinical trials as a synergistic 
cancer treatment, the side effects of this combination are still unfavorable [278, 281]. 
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Figure 6.1 Formation of polymer-drug complex micelle between the glutamic acid 
groups of co-polymers (PEG-PLA and FOL-PEG-PLA) and two anticancer drugs DOX 
and CDDP. 
 
To overcome the limitation caused by the side effects of CDDP and DOX, various 
methods have been studied to deliver CDDP and DOX to tumor tissues with lesser side 
effects by encapsulating drugs into carriers. Micelles, liposomes and nanoparticles are 
commonly used carriers for the delivery of a single drug CDDP [105, 282-285] or DOX 
[286, 287], or dual drugs CDDP/DOX [288]. A recent study has demonstrated that the 
combination therapy of DOX and CDDP using a nano-carrier system could improve the 
efficacy of advanced breast cancers while decreased clinical toxicity compared with the 
combined free DOX and CDDP treatment in vivo [289]. In addition to the delivery of 
drugs using a nano-carrier system, the therapeutic efficacy can be further improved by 
modifying the delivery carrier with a ligand that is able to target to specific cancer cells 
of interest. Folate (FOL) is a targeting ligand having high binding affinity to folate 
receptors overexpressed in ovarian, breast, brain, lung, colorectal cancer cells  [253-255] 
and has widely been used to modify many delivery carriers such as nanoparticles [87], 
liposomes [256], micelles [257-260]. 
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Figure 6.2 Active targeting co-delivery of DOX and CDDP to cancer cells by the 
modification of carriers with FOL which has high binding affinity to cancer cells by two 
methods: (A) injection of DOX- FOL micelles and CDDP-FOL micelles; (B) injection of 
CDDP/DOX-FOL micelles which encapsulate both CDDP and DOX at the designed ratio 
in a micelle. 
 
Herein, our approach was to investigate CDDP and DOX delivery systems utilizing the 
benefits of (1) combined CDDP and DOX treatment, (2) delivery of drugs using micellar 
carriers, and (3) modification of carrier’s surface with FOL targeting ligand. In addition, 
to obtain high encapsulation amount of CDDP and DOX, poly(ethylene glycol)-
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poly(glutamic acid) (PEG-PGA) and folate-PEG-PGA (FOL-PEG-PGA) polymers were 
chosen to form drug carriers for this study (Fig. 1). The polymer-drug complex formation 
between PEG-PGA/FOL-PEG-PGA polymers and drugs CDDP or DOX was due to the 
ligand substitution reaction at platinum atoms of CDDP and carboxylic groups of PGA 
block [105], and the electrostatic interaction of the negatively charged PGA block and the 
cationic drug DOX [109, 286] respectively (Figure 6.1). In vitro cytotoxicity studies were 
carried out based on the three methods of CDDP/DOX delivery. Firstly, the effects of 
different free drug combinations (CDDP/DOX) on cancer cells was investigated to find 
out the combination that exhibits good synergy over a wide treatment concentration range 
for subsequent drug-encapsulating studies. Secondly, co-delivery of two single drug-
loaded micelles using FOL modified system (CDDP-FOL micelles & DOX-FOL 
micelles) in Figure 6.2A.  Finally, dual drugs-encapsulated micelles with FOL 
modification (Figure 6.2B) were evaluated.  
 
6.2 Experimental section 
6.2.1 Materials 
Poly(ethylene glycol) bis(amine) (PEG-diamine, Mw:10,000) were purchased from 
Laysan Bio Inc (USA). Bis(trichloromethyl) carbonate (triphosgene), β-benzyl l-
glutamate, poly(ethylene glycol)-amine (PEG-amine, Mw: 5,000), N-hydroxysuccinimide 
(NHS), dicyclohexyl carbodiimide (DCC), folic acid, cis-diamminedichloroplatinum (II) 
(cisplatin, CDDP), 3-[4,5-dimethylthiazolyl-2]-2,5-diphenyl tetrazolium bromide (MTT), 
hydrochloric acid (HCl) and platinum (Pt) standard solution 1000 mg/L in 5% 
hydrochloric acid  were all purchased from Sigma-Aldrich (USA). Doxorubicin (DOX) 
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was obtained from Boryung (Korea). Pyridine, chloroform, dichloromethane (DCM), 
N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), anhydrous 
tetrahydrofuran (THF), methanol, 2-propanol, diethyl ether and hexane were purchased 
from Tedia (USA). Folate-free RPMI 1640 medium, fetal bovine serum (FBS), Trypsin-
EDTA and penicillin-streptomycin were obtained from Invitrogen (USA). All chemicals 
were used directly without further purification. KB human oral cavity carcinoma cell line 
was purchased from ATCC (USA). 
 
6.2.2 Synthesis and characterization of polymers 
6.2.2.1 Synthesis of polymers 
Two block copolymers, poly(ethylene glycol)-poly(glutamic acid) (PEG-PGA) and 
folate-PEG-PGA (FOL-PEG-PGA) were used in this study as carrier materials. 
PEG-PGA was synthesized using a three-step protocol as insulated in Figure 6.3 [105]. 
Firstly, the N-carboxy anhydride of β-benzyl l-glutamate was synthesized using an 
equivalent of triphosgene in THF at 50°C in the N2 atmosphere. The reaction took 3 
hours to get a completely homogeneous solution of N-carboxy anhydride of β-benzyl l-
glutamate which was then poured into ice-cold hexane and stored at -20°C overnight to 
assure complete crystallization. The crystallized N-carboxy anhydride of β-benzyl l-
glutamate was collected and dried in the vacuum oven at room temperature to remove the 




Figure 6.3 Schematic of PEG-PGA and FOL-PEG-PGA synthesis.  
 
Secondly, PEG-poly(g-benzyl L-glutamate) was synthesized by the ring opening 
polymerization reaction of N-carboxy anhydride of β-benzyl l-glutamate with PEG-
amine as the initiator in DMF/chloroform at 35°C in N2 atmosphere for 3 days. The 
resultant solution was dropped into ice-cold diethyl ether to precipitate PEG-poly(β-
benzyl L-glutamate) and the product was dried in a vacuum oven. Finally, PEG-PGA was 
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produced by the deprotection of the benzyl groups of PEG-poly(β-benzyl l-glutamate) in 
0.5 M NaOH in a mixture of water/methanol/2-propanol at volume ratio of 1/2/2 at 0°C 
for 15 min [36]. The solution was poured into ice-cold diethyl ether to precipitate PEG-
PGA. The precipitant was dissolved in DI water and dialyzed against DI water for two 
days and freeze-dried. 
 
FOL-PEG-PGA was synthesized from the polymerization reaction between FOL-PEG-
amine and N-carboxy anhydride of β-benzyl l-glutamate and followed by the 
deprotection of the benzyl groups. The synthesis of FOL-PEG-PGA was in the same 
mechanism with PEG-PGA synthesis with the additional of the coupling reaction of FOL 
to PEG before the polymerization reaction [257]. First, FOL was conjugated to PEG-
diamine (Mw: 10,000) using DCC/NHS (molar ratio of PEG-diamine:folic 
acid:DCC:NHS = 1:1:2:2) in DMSO in the presence of pyridine for 10 h in the dark. The 
resultant solution was purified by being diluted with de-ionized (DI) water and 
centrifuged to remove the insoluble by-product dicyclohexylurea (DCU). The supernatant 
was further filtered to obtain clear yellow solution before being dialyzed against DI water 
for 2 days (MWCO: 1000) to remove DMSO and unreacted FOL and freeze-dried. The 
trace amount of unreacted PEG-diamine was then removed by batch adsorption with 
cellulose phosphate cation exchange resin using 5 mM phosphate buffer pH 7.0 as the 
start buffer. PEG-FOL was further purified by a DEAE sephadex anion exchange column 
with 20 mM Tris-HCl pH 8.0 as the start buffer to remove FOL-PEG-FOL by-products. 
The final product was precipitated twice in ice-cold diethyl ether, dissolved in DMSO for 
dialysis against DI water for 2 days (MWCO: 10,000), centrifuged, and then freeze-dried. 
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6.2.2.2 Characterization of polymers 
The synthesized co-polymers, PEG-PGA and FOL-PEG-PGA, were characterized by gel 
permeation chromatography (GPC) and 1H nuclear magnetic resonance (1H NMR). GPC 
analysis was performed in an Agilent HPLC 1200 equipped with a TSK GEL 
G4000PWXL (4.6 mm × 300 mm, 10 µm) column and a refractive index (RI) detector. 
100 mM NaCl in PBS was used as a mobile phase at the flow rate of 1 mL/min at 40°C. 
1H NMR was carried on in a Bruker AMX 500 at 80°C using D2O as a solvent. 
 
6.2.3 Preparation and characterization of cisplatin (CDDP) and doxorubicin (DOX) 
micelles 
The micelles were prepared by dissolving polymers (PEG-PGA, FOL-PEG-PGA) and 
drugs (CDDP and DOX) in DI water to obtain a concentration of 5 mmol/L glutamic acid 
(GA). The molar ratio of drugs and polymers were kept at [molar of drugs]/[molar of 
GA] = 1/1 followed the previous study’s protocol [105]. The solutions of polymers and 
drugs were kept at 37°C for 3 days under shaking condition for the formation of the 
polymer-drug complex micelles as shown in Fig. 1. The micelles were purified by 
dialyzing against DI water for 6 h to remove untrapped drugs.  
 
The hydrodynamic size and zeta potential of polymeric micelles were measured at 25°C 
by a NanoSizer (Malvern Instruments, UK). Aqueous micelle solutions were prepared 
using deionized water. The concentration of polymeric micelles was kept at 1 mg/ml. The 
micelle solutions were filtered through a 0.80 µm cellulose membrane filter before 
measurements. The average values were calculated from at least 3 measurements 
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performed on each samples. The CDDP loading content in the micelles was determined 
by dissolving the micelles in 5% HCl and measuring the Pt concentration of the solution 
using an inductively coupled plasma-mass spectrometer (ICP-MS; Perkin-Elmer, Elan 
6100). The DOX loading content in the micelles was estimated with a UV-vis 
spectrophotometry at 480 nm by dissolving 1 mg of DOX- loaded micelles in 1 ml 
DMSO.  
 
6.2.4 In vitro release study 
Micelle solutions (1 mg in 1 ml of PBS, pH 7.4) were transferred to dialysis tube 
(MWCO: 2,000 Da) and dialyzed against 3 ml PBS in a tube at 37°C with shaking at 100 
rev/min. To measure the release of drugs at different time intervals, PBS solution in the 
tube was all withdrawn and replaced with 3 ml fresh PBS. To determine the released 
amount of CDDP, 10% HCl was added into the withdrawn solution to obtain the solution 
with 5% HCl and measured by ICP-MS. The released amount of DOX in the withdrawn 
solutions was transferred into a 96-well plate and analyzed by a microplate reader with 
excitation wavelength at 480 nm and emission wavelength at 570 nm. The drug release 
studies were performed in triplicate for each of the samples. 
 
6.2.5 In vitro cytotoxicity study 
The ability of various treatments to inhibit cell proliferation was evaluated using human 
carcinoma KB cell line with MTT viability assay. Cells cultured in free folic RPMI 
media supplemented with 10% FBS and 1% penicillin-streptomycin at 37°C in 
humidified environment of 5% CO2 were seeded onto 96-well plates at a seeding density 
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of 10,000 cells/well and incubated for 2 days to permit cell attachment. The cells were 
then treated with free drugs or micelles at different concentrations for 3 days. Afterwards, 
the cell viability was determined by MTT assay following the method as described in 
Chapter 4.  The combination index of the combined treatments was determined by Chou 
and Talalay’s principle as mentioned in Chapter 2 and 4. The toxicity of all blank 
micelles was tested at a high concentration of 2.0 mg/mL and exhibited non-toxic to KB 
cells. This observation is in agreement with previous studies and indicates the suitability 
of the micellar system for carrying anticancer drugs. 
 
6.3 Results and discussion 
6.3.1 Characterization of polymers 
The two polymers, PEG-PGA and FOL-PEG-PGA, were prepared by alkaline hydrolysis 
of PEG- or FOL-PEG-poly(g-benzyl L-glutamate), which were the products of the 
polymerization of N-carboxy anhydride of β-benzyl l-glutamate with amine initiators 
(PEG-amine or FOL-PEG-amine). Therefore, the degree of polymerization of the PGA 
blocks of PEG-PGA and FOL-PEG-PGA were determined by the changes in the 
molecular weight of PEG-PGA and FOL-PEG-PGA compared to that of PEG and FOL-
PEG respectively. From GPC results (Figure 6.4A and 6.4C), the polymerization degrees 
of PGA blocks of PEG-PGA and FOL-PEG-PGA are estimated at 60 and 53 respectively. 
After the polymerization and alkaline hydrolysis to deprotect the benzyl group, the 
resultant polymers were purified to remove unreacted PEG or FOL-PEG and other small 
molecules such as monomer, solvents. The GPC spectra in Figure 6.4A and 6.4C show 
that the purification steps are able to remove completely unreacted PEG or FOL-PEG 
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from the products. However, there is a trace amount of small molecule impurities in the 
final products. From the 1H NMR spectra, the protons of PGA block are observed at δ = 
4.67, 2.20, 1.80-1.98 ppm [290], the protons of the PEG block are at δ = 3.5-3.7 ppm 
[291], and peaks at δ 6.6 and δ 7.6 are from FOL [257]. The absence of the residual 
benzyl group (δ = 7.3 pmm) in the 1H NMR spectra of the synthesized polymers (Figure 
6.4B and 6.4D) confirms the completion of the alkaline hydrolysis reaction. The above 
analysis results indicate that PEG-PGA and FOL-PEG-PGA were successfully prepared.   
 
Figure 6.4 GPC and 1H NMR spectra of PEG-PGA (A and B respectively) and FOL-
PEG-PGA (C and D respectively). 
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6.3.2 In vitro cytotoxicity interaction between free cisplatin (CDDP) and free 
doxorubicin (DOX)  
This study was designed for the investigation of the delivery system for CDDP and DOX 
at the synergistic ratio. Therefore, the combined effects of free CDDP and free DOX 
cancer cells at various ratios were firstly studied to obtain the synergistic ratio that was 
subsequently used for drug delivery studies. KB cell line was used as a model for all 
experiments. The combinations of free CDDP and free DOX are presented as 
CDDP/DOX_x/y while x/y is the molar ratio of CDDP/DOX in the combination.  
 
Table 6.1 IC50 of different treatment compositions of free drugs, CDDP and DOX  
 









As shown in Figure 6.5A, the cell viability is gradually decreased as the increase of 
CDDP/DOX ratio from 1/1 to 40/1. However, the cell viability is almost unchanged when 
the CDDP/DOX ratio increases to 60/1, and this indicates that CDDP/DOX_60/1 
treatment may not provide better synergistic effect than CDDP/DOX_40/1 treatment. 
From the IC50 values (the required dose to kill 50% cells) in Table 6.1, the treatment with 
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higher CDDP/DOX ratio results in lower IC50 of DOX but higher IC50 of CDDP. 
Therefore, it is impossible to determine the synergistic regimes from the data in Figure 
6.5A and Table 6.1. Therefore, further analysis needs to be carried on these cytotoxicity 
results to obtain the more quantitative data using Calcusyn software that has been 
commonly used to study the effect of combined drug treatments by calculating the CI 
values of combinations at fixed ratios as a function of the cell viability [219, 272, 288]. 
The effect of combination treatments is considered as a synergistic combination with CI 
values below 1 for all treatment concentrations that provide the cell viability from 5% to 
95%. From Figure 6.5B, CI values of CDDP/DOX_1/1 and CDDP/DOX_60/1 show 
synergistic effect at low treatment doses but antagonistic effect (CI > 1) at high treatment 
doses. Therefore, these two treatment combinations are not considered as synergistic 
regimes in this study. Three combinations at CDDP/DOX ratios of 10/1, 20/1 and 40/1 
show synergistic effect for all treatment doses. Comparing among these three synergistic 
regimes, the CDDP/DOX_10/1 shows the highest CI values which indicate the lowest 
synergistic effect of CDDP/DOX_10/1. Between CDDP/DOX_20/1 and 
CDDP/DOX_40/1, the treatment with CDDP/DOX_20/1 exhibits higher synergistic 
effect at low treatment doses while the treatments with CDDP/DOX_40/1 at high doses 
show better synergistic effect. IC50 values of the two treatments in Table 6.1 show that 
the treatment with CDDP/DOX_20/1 reduces 45% required dose of CDDP compared to 
the treatment with CDDP/DOX_40/1 to kill 50% cancer cells. Therefore, the combination 
of CDDP and DOX at the composition of CDDP/DOX_20/1 is more favorable to the 




Figure 6.5 The combined effects of various CDDP/DOX ratios as presented by (A) the cytotoxicity respond of KB cells vs DOX 




6.3.3 Characterization of drug-loaded micelles  
Two classes of polymer-drug complex micelles, single drug-loaded micelles (CDDP-
micelles, CDDP-FOL micelles, DOX- micelles, DOX- FOL micelles) and dual drugs-
loaded micelles (CDDP/DOX(20/1)-FOL micelles) were prepared for this study. 
CDDP/DOX(20/1)-FOL micelles indicate that this dual encapsulated system contains 
both CDDP and DOX in a micelle at the molar ratio of CDDP/DOX of 20/1.  
 
Table 6.2 Characterization of polymeric micelles.  
 
Table 6.2 shows that the encapsulation of CDDP and DOX using this method can 
produce polymer-drug complex micelles with very high drug loading content (DLC) up 
to 26 % and 48% for CDDP and DOX encapsulation respectively. DLC of DOX is higher 
than that of CDDP can be due to the additional strong π-π interaction of DOX molecules 
besides the electrostatic interaction between DOX and PGA. Compared with recently 
reported CDDP and DOX-loaded systems such as systems from poly(γ, L-glutamic acid)-
citric acid-cisplatin with the loading of CDDP at 20% [292], folate-poly(ethylene glycol)-
poly(ε-caprolactone) with the loading of DOX at 4.6 – 13% [293], and mPEGylated 
Micelles DLC   (%) 






CDDP-micelles  26.1 52.6 167.0 -16.8 
CDDP-FOL micelles  23.8 48.1 181.0 -14.5 
DOX-micelles  48.4 65.0 190.7 -4.6 
DOX-FOL micelles  45.5 61.2 205.6 -4.12 




peptide dendron–DOX with the loading of DOX at 14% [294], the systems in this study 
are more favorable in term of DLC. All drug-loaded micelles in this study have the size 
from 167 nm to 205.6 nm with negative zeta potentials of approximately -5 to -15 mV 
(Table 6.2). The slightly negative zeta potentials of drug-loaded micelles can prevent the 
non-specific binding between the micelles and the cells due to the negative zeta potentials 
of most biological cells [295]. In addition, the modification of micelles with FOL moiety 
allows the drug-loaded micelles to accumulate specifically into the cancer cells via 
receptor-mediated interaction. These properties indicate the suitability of these systems 
for drug delivery application [273, 274]. 
 
6.3.4 In vitro drug release study 
The release rates of CDDP and DOX from the polymer-drug complex micelles in PBS, 
pH 7.4 at 37°C are shown in Figure 6.6. Clearly, CDDP releases faster than DOX in all 
formulations due to the additional π-π interaction of DOX molecules besides the 
electrostactic interaction between DOX and PGA. The drug release profiles CDDP or 
DOX of singe-drug loaded micelles without FOL (CDDP-micelles and DOX- micelles) 
in Figure 6.6A and with FOL modification (CDDP-FOL micelles and DOX- FOL 
micelles) in Figure 6.6B are quite similar. However, DOX releases faster in the dual 
CDDP/DOX(20/1)-FOL micelles while CDDP releasing rate remains similar to that of 
CDDP-FOL micelles. The faster release rate of DOX in the dual system may due to the 
disruption of π-π interaction between DOX molecules by the presence of CDDP.   
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Figure 6.6 In vitro drug release of CDDP and DOX from: (A) CDDP-micelles and DOX- micelles, (B) CDDP-FOL micelles and 
DOX- FOL micelles, and (CDDP) CDDP/DOX(20/1)-FOL micelles. The experiments were conducted in triplicate. The standard 
deviation is less than 10%. 
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After the first 72 h of release, approximately less than 35% and 25% of CDDP and DOX 
are released respectively. Compare with recently reported studies as mentioned above 
(Section 6.3.3), the poly(γ, L-glutamic acid)-citric acid-cisplatin system with 50% CDDP 
release within first 72 h [292], folate-poly(ethylene glycol)-poly(ε-caprolactone) with 
42% DOX release within the first 24 h [293], and mPEGylated peptide dendron–
doxorubicin with 20% DOX release in the first 24 h [294], the micellar systems in this 
study show better sustainable release. 
 
6.3.5 Cytotoxicity enhancement of drug-loaded micelles with the addition of FOL on 
the micelle surface 
 
Table 6.3 IC50 of different micellar treatments: (1) delivery of single drug-loaded 
micelles, (2) co-delivery of two singe drug-loaded micelles at the ratio of CDDP/DOX at 
20/1, and (3) delivery of dual drugs-loaded micelles at the ratio of CDDP/DOX at 20/1. 
Treatment IC50 (µM) 
(1) Delivery of single drug-loaded micelles: 
 
CDDP-micelles 8.467 
CDDP-FOL micelles 3.511 
DOX-micelles 0.364 
DOX-FOL micelles 0.170 
(2) Co-delivery of two single drug-loaded micelles: 
CDDP-FOL micelles & DOX-FOL micelles_20/1 
0.768/0.038 






Figure 6.7 Effect of FOL modification on the treatment efficacy of CDDP and DOX loaded micelles to KB cells as investigated using 
(A) DOX- loaded micelles and (B) CDDP-loaded micelles. 
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The enhancement effect of FOL modification onto the treatment efficacy of drug-loaded 
micelles was investigated using single drug-loaded micelles of both anticancer drugs 
CDDP and DOX on KB cells. Figure 6.7 show that the FOL modified micelles (CDDP-
FOL micelles and DOX- FOL micelles) exhibit lower degree of cancer cell viability than 
that of non-modified micelles (CDDP-micelles and DOX- micelles). Based on the IC50 
values (Table 6.3), FOL-modified micelles show more than 2 times higher therapy 
efficacy than non-modified micelles. The high binding affinity of FOL with cancer cells 
can increase cellular uptake of FOL-modified into cancer cells (Figure 6.8) and results in 
higher cancer treatment efficacy. From the IC50 values, it can be seen that the 
enhancement in therapy efficacy of CDDP-FOL micelles versus free CDDP is 
approximate 2.6 times while that enhancement of DOX- FOL micelles versus free DOX 
is only approximate 1.7 times. It means that the FOL-micellar system is more effective 
for the treatment using free CDDP than that of free DOX.  This observation is in 
agreement with the rapid development of CDDP resistance to cancer cells compared with 
other non-platinum based drugs as observed by previous studies [277]. 
 
Figure 6.8 In vitro cellular uptake of DOX micelles and DOX-FOL micelles into KB 
cells. 
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6.3.6 Synergistic effect of the co-delivery of CDDP-loaded micelles and DOX- loaded 
micelles 
Based on the preliminary study of free CDDP and free DOX combinations, the 
CDDP/DOX combinations at molar ratios from 20/1 to 40/1 show synergistic effect for 
the treatment doses that result in 5-95% cell viability. In addition, the FOL-modified 
micelles demonstrates higher cancer treatment efficacy than non-modified micelles as 
shown in Section 6.3.5. In this section, co-delivery of two single drug-loaded micelles 
was conducted using CDDP-FOL micelles & DOX-FOL micelles (Figure 6.2A) at the 
molar ratio of drugs in the two micellar systems of 20/1 (CDDP/DOX). This co-delivery 
system is noted as CDDP-FOL micelles & DOX-FOL micelles_20/1.  
 
The higher cancer treatment efficacy of CDDP-FOL micelles & DOX-FOL 
micelles_20/1 compared to single-drug loaded micellar treatment is shown as the lower 
required treatment dose at the same treatment effect (Figure 6.9A and 6.9B). From Tables 
6.3, the required dose to kill 50% KB cells (IC50) of the CDDP-FOL micelles & DOX-
FOL micelles_20/1 system is approximately 11 and 9.6 times lower than that of CDDP-
micelles & DOX-micelles respectively. In quantitative comparison between the treatment 
efficacy of co-delivery system (CDDP-FOL micelles & DOX-FOL micelles_20/1) and 
single drug-loaded FOL micelles (CDDP-FOL micelles and DOX-FOL micelles), the CI 
values of the co-delivery system as the function of cell viability are presented in Figure 
6.9C. Obviously, co-delivery of single drug-loaded micelle system is a synergistic 
treatment with all CI values < 1 for the wide range of treatment concentrations which is 
the same phenomenon as observed in the CDDP and DOX combination (Section 6.3.1). 
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This co-delivery of two single drug-loaded micellar system can potentially be a more 
flexible method to obtain the synergistic treatment compared with the delivery of dual 
drugs-loaded micelles (Figure 6.2B). Because the combined ratios in the co-delivery of 
two single drug-loaded micelle system can be easily varied for specific treatment. 
 
Figure 6.9 Cytotoxicity dose response of KB cells with various CDDP/DOX delivery 
strategies: (A-B) the co-delivery of two single drug-loaded FOL micelles (Figure 6.2A) at 
CDDP/DOX ratio of 20/1 compared to DOX- micelles and CDDP-micelles, respectively; 
and (CDDP-D) the dual drugs-encapsulated FOL micelles (Figure 6.2B) at the 
encapsulated CDDP/DOX ratio of 20/1 compared to DOX- micelles and CDDP-micelles 
respectively. Synergistic effects of the co-delivery of CDDP-FOL micelles & DOX- FOL 
micelles and the dual CDDP/DOX-FOL micelles treatment at the molar ratio of 
CDDP/DOX of 20/1 were presented as the CI values as the function of cell viability. 
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6.3.7 Synergistic effect of dual drugs-loaded micelles  
CDDP-FOL micelles & DOX- FOL micelles_20/1 has been demonstrated as a synergistic 
co-delivery system for KB cell treatment. Therefore, a dual drugs-loaded FOL system at 
the molar ratio of CDDP/DOX of 20/1 has been fabricated to study its synergistic effect 
as well as to compare with the co-delivery system (CDDP-FOL micelles & DOX- FOL 
micelles_20/1). The dual drugs-loaded FOL system is presented as CDDP/DOX(20/1)-
FOL micelles with the molar ratio of CDDP/DOX in a micelle of 20/1. As shown in 
Figure 6.9B, dual CDDP/DOX micelles with FOL modification show the higher cancer 
treatment efficiency than CDDP- or DOX- micelles. This phenomenon is similar to the 
co-delivery system as shown in Figure 6.9A. The IC50 values of CDDP-FOL micelles & 
DOX- FOL micelles_20/1 system and CDDP/DOX(20/1)-FOL micelle system are 0.768 
µM (CDDP)/0.038 µM (DOX), 0.650 µM (CDDP)/0.032 µM (DOX) respectively as 
tabulated in Table 6.3. Based on the IC50 values and the CI values (Figure 6.9C) of the 
two systems, the dual drugs-loaded system seems slightly better than the co-delivery of 
two single drug-loaded system. This observation can be due to the faster release of DOX 
from the dual drugs-loaded system (Figure 6.6C) as well as the higher possibility of 
synergistic ratio of accumulated drugs in cancer cells using the dual drugs-loaded system. 
 
Between the co-delivery system (CDDP-FOL micelles & DOX-FOL micelles_20/1, 
Figure 6.2A) and the dual system (CDDP/DOX_20/1-FOL micelles, Figure 6.2B), the 
dual system exhibits better delivery and treatment efficacy properties due to its higher 
ability in delivering the designed combination of therapeutic agents to the targeted 
tumors. Therefore, the dual system is more favorable for most cancer treatments. 
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However some special cases need special combined regimes, the co-delivery system may 
be applied as the combination ratio can be varied easily. 
 
6.4 Conclusions 
This study has demonstrated that the encapsulation of CDDP and DOX using PEG-
PGA/FOL-PEG-PGA polymers as carrier materials provides polymer-drug complex 
micelles with high drug loading content of up to 26% (CDDP) and 48% (DOX) at 
sustained drug release. Combined synergistic CDDP/DOX treatments have been 
demonstrated using three methods: simultaneously delivery of free CDDP and free D, co-
delivery of two single drug-loaded FOL micelles (CDDP-FOL micelles & DOX- FOL 
micelles_20/1) and dual drugs-loaded FOL micelles (CDDP/DOX(20/1)-FOL micelles. 
The combined treatments via FOL-micellar systems exhibit higher efficacy than free 
CDDP/DOX treatment due to the high binding affinity of the FOL to the cancer cells.  
The two combined methods via micellar systems (co-delivery and dual) show quite 
similar synergistic effect with slightly higher efficacy in the dual system. Although the 
co-delivery of two single drug-loaded FOL micelles and the dual drugs-loaded FOL 
micelles show slightly different in vitro studies, they contain their own advantage and 
limitation. For the co-delivery of two single drug-loaded micelles, the combination ratio 
could be easily varied for specific treatment with the limitation of maintaining the 
designed ratio in vivo treatment. The dual drugs-loaded micelles have higher possibility 
in maintaining the initial drug ratio for in vivo application which could overcome the 
limitation of the co-delivery of two single drug-loaded micelles. However, the variation 
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of drug ratios of the two drugs in the dual drugs-loaded micelles would require further 
optimization for specific applications. 
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CHAPTER 7. Conclusions and Recommendations  
 
7.1 Conclusions 
This thesis has been investigated the application of targeted nanotechnology for drug 
delivery in cancer therapy. Targeting micellar systems from biocompatible and 
biodegradable polymers have been designed to deliver different types of anticancer drugs 
in single-drug therapeutic or combined-drugs therapeutic methods. This thesis has three 
main duties: (i) synthesis of block copolymers as the materials for micellar formations, 
(ii) demonstration of surface modified polymeric micellar systems as the drug delivery 
carriers for the enhancement of targeting ability and cellular uptake, and (iii) 
demonstration of the synergistic therapeutic effect of combined chemotherapy based on 
two anticancer drugs via targeting micellar carriers. 
 
This thesis has been studied different micellar systems for various drug delivery 
applications. Various micellar systems have been investigated to demonstrate the 
targeting delivery of (i) hydrophobic drugs based on hydrophobiCDDP-hydrophobic 
interaction, (ii) platinum-based drugs based on the polymer-metal complexation, and (iii) 
positive charged-drugs via the electrostatic interaction. In order to achieve the above 
aims, two block copolymer systems PLGA-PEG and PEG-PGA have been synthesized. 
PLGA-PEG polymer has been used to deliver hydrophobic drugs via the hydrophobic 
interaction between PLGA block and hydrophobic drugs. For delivering of platinum-
based drugs or positive charged-drugs, PEG-PGA polymer has been applied due to the 
polymer-metal complexation between platinum-based drugs and carboxylic groups of 
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PGA block or electrostatic interaction between the negative charged carboxylic groups 
and positive charged-drugs. Moreover, the two polymer systems have been modified with 
FOL or TAT so that the resultant micelles exhibit cancer targeting ability and high 
cellular uptake. The results of this study show that the presence of FOL on the carrier 
surface can enhance the cellular uptake of the drug-loaded carriers into the cancer cells 
that leads to the higher cancer treatment efficacy. Besides FOL modification, this study 
also proves that the efficacy of the drug delivery systems can be further improve by 
multi-modifying the carrier surface with both FOL and TAT.  
 
To utilize the synergistic effect of combined-anticancer drugs and the advanced targeting 
drug delivery systems that mentioned above, combined-anticancer drug treatments using 
surface modified micelles have been studied for delivering of two anticancer drugs in a 
micellar system (called as dual-drugs loaded micellar system) or  in two separated 
micellar systems (called as co-delivery of two single drug-loaded micelle system). Three 
pairs of anticancer drugs including combination of two chemo-drugs DOX/PTX, 
combination of a chemo-drug and a hormone drug P/T, and combination of a platinum-
based drug and a non-platinum-based drug CDDP/DOX have been studied for treatments 
of solid tumors, breast cancer, and solid tumors respectively. This study has demonstrated 
the enhancement of cancer treatment efficacy of the designed systems, which combine 
the advantages of micellar systems, targeting ability and uptake ability of ligands, and 
combined treatment of two different mechanism anticancer drugs, compared to the 
common delivery method using single drug delivery systems. This study also 
demonstrated and discussed the differences of the combined treatments between a dual-
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drugs loaded micellar system and a co-delivery of two single drug-loaded micelle system. 
Due to the variation of cancer disease, the chemotherapeutic drugs are varied case by 
case based on the specific cancer and the patient respond. Therefore, the co-delivery 




As proven in this work, the targeted dual drugs-loaded system shows promising data for 
cancer treatments. The targeting delivery of dual drugs-loaded technology may be further 
developed and move forward for clinical use. The author would like to make some 
recommendations for future studies. 
 
Having developed the multi-modified carriers, the next phase of this study can investigate 
the structure of the polymers which will further increase the pharmacodynamics 
properties of these drug delivery systems. This should be achievable by tuning different 
parameters such as the purity, the ratio of hydrophilic/hydrophobic block, and the 
molecular weight of copolymers.  
 
It is well known that the behavior of treatment systems may not always be similar 
between in vitro and in vivo studies. Therefore, in vivo studies should be carried out for 
further evaluations of this developed technology. First, tissue distribution of combination 
agents needs to be investigated to evaluate the efficiency of the co-delivery system and 
the dual system in delivery of combination drugs at designed regimes. Second, in vivo 
 147 
antitumor efficacy should be study against various treatment technologies such as single 
drug-loaded system, co-delivery of two single-drug loaded system, dual drugs-loaded 
system. Body weight and mortality should also be monitored. 
 
In this work, the micellar carriers have promisingly been demonstrated for 
simultaneously therapeutic drug delivery but they are only potential to co-encapsulate 
hydrophobic drug molecules or hydrophilic/hydrophobic drugs which exhibit special 
chemical interactions with polymers. As such, this property may limit some applications 
of micelles especially in the combined-drug treatments using drugs with different 
chemical/physical properties. Therefore, the author would recommend using 
polymersomes as carriers for delivery of anticancer drugs.   
 
Polymersomes have recently been studied as new type of carriers for drug delivery 
because they act as stable polymer systems that can carry both hydrophilic and 
hydrophobic drugs. Polymersomes are composed of synthetic amphiphilic polymers and 
have similar vesicle structure to liposomes (Figure 7.1).  
 
Figure 7.1 Schematic of preparation of drug-loaded polymersomes. 
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Compared to liposomes, polymersomes have been shown superior properties, including 
higher stability, larger storage capability, and sustained drug circulation time [296]. 
Moreover, the surface of polymersomes can be easily functionalized as block copolymer 
chemistries can be tailored via the synthesis processes. Besides, the above mentioned 
advantages of polymersomes, their drug loading capability in the shell can easily be 
tailored by varying the molecular weight (MW) of the hydrophobic block in the 
copolymer (Figure 7.2). Therefore, this new drug delivery technique has attached 
researchers recently [297-299].  
 
Figure 7.2 Schematic scaling of polymersome membrane thickness with copolymer 
molecular weight (MW) [300]. 
 
The vesicle morphologies of polymersomes are determined by the volume fraction of 
each block in copolymers. Generally, polymersomes are formed when the ratio of 
hydrophilic block to total polymer mass of approximately ≤ 35 ± 10 (%) as illustrated in 
Figure 7.3. Micelles or inverted microstructures are formed if that ratio is greater than 
45% or less than 25% respectively.  
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Figure 7.3 Schematics of self-assemble structures of block copolymer at various ratios of 
hydrophilic to total copolymer mass [300]. 
 
 
Polymersomes present as more advantage delivery systems when compared to micelles 
because they can simultaneously encapsulate hydrophobic drugs within their membrane 
and hydrophilic drugs in their aqueous interior. Despite of their superior properties, the 
development of polymersome drug delivery systems is still limited to in vivo study 
because of the difficulty in controlling their size, structure and surface modifications.       
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